WO2010071988A1 - Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging - Google Patents

Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging Download PDF

Info

Publication number
WO2010071988A1
WO2010071988A1 PCT/CA2009/001853 CA2009001853W WO2010071988A1 WO 2010071988 A1 WO2010071988 A1 WO 2010071988A1 CA 2009001853 W CA2009001853 W CA 2009001853W WO 2010071988 A1 WO2010071988 A1 WO 2010071988A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ppi
chch
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2009/001853
Other languages
French (fr)
Other versions
WO2010071988A8 (en
Inventor
Amin M. Khan
Paul L. Wood
Dayan Goodenowe
Rishikesh Mankidy
Pearson Ahiahonu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenomenome Discoveries Inc
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0922619A priority Critical patent/BRPI0922619A8/en
Priority to MX2011006795A priority patent/MX350291B/en
Priority to KR1020117015617A priority patent/KR101810988B1/en
Priority to RU2011124579/04A priority patent/RU2546108C2/en
Priority to CA2746831A priority patent/CA2746831C/en
Priority to SG2011045994A priority patent/SG172340A1/en
Priority to AU2009329784A priority patent/AU2009329784B2/en
Priority to EP09833973.2A priority patent/EP2382201B1/en
Priority to CN200980157183.5A priority patent/CN102369193B/en
Priority to JP2011541046A priority patent/JP5740312B2/en
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Priority to US13/141,035 priority patent/US9334235B2/en
Publication of WO2010071988A1 publication Critical patent/WO2010071988A1/en
Priority to IL213409A priority patent/IL213409A0/en
Anticipated expiration legal-status Critical
Publication of WO2010071988A8 publication Critical patent/WO2010071988A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides

Definitions

  • the present invention relates to the synthesis and utility of novel chemical entities with useful biochemical, physiochemical, and clinical properties. More specifically, a series of 1-alkyl, 2-acyl glycerol derivatives are provided which can be used for the treatment or prevention of disease. The invention also relates to pharmaceutical compositions and kits incorporating such compounds.
  • Subjects suffering from increased membrane cholesterol demonstrate an increased prevalence of neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, multiple sclerosis and age- related macular degeneration), cognitive impairment, dementia, cancers (e.g. prostate, lung, breast, ovarian, and kidney), osteoporosis, bipolar disorder and vascular diseases (atherosclerosis, hypercholesterolemia).
  • neurodegenerative diseases e.g. Alzheimer's, Parkinson's, multiple sclerosis and age- related macular degeneration
  • cognitive impairment e.g. Alzheimer's, Parkinson's, multiple sclerosis and age- related macular degeneration
  • dementia e.g. Alzheimer's, Parkinson's, multiple sclerosis and age- related macular degeneration
  • cancers e.g. prostate, lung, breast, ovarian, and kidney
  • osteoporosis e.g., bipolar disorder and vascular diseases (atherosclerosis, hypercholesterolemia).
  • cholesterol accumulates in the brain membranes of Alzheimer's patients in a severity-dependent manner 12"14 .
  • lowering membrane cholesterol has been shown to decrease the activities of beta- and gamma-secretases, blocking the pathogenic processing of beta-amyloid 15"16 .
  • cholesterol binds to the transmembrane domain of amyloid precursor protein (APP), activating the trafficking of APP to cholesterol-rich membrane domains rich in beta- and gamma-secretases, resulting in amyloid-beta production 17 .
  • APP amyloid precursor protein
  • Synaptic membrane changes resulting from increased cholesterol may also be an important factor in the utilization of membrane phospholipids to support cholinergic neurotransmission (autocannibalism concept) 18 .
  • oxysterols are cytotoxic (apoptosis and necrosis), pro-inflammatory, deplete GSH and induce phospholipidosis 23"26 .
  • Diseases in which these toxic oxysterols might be involved include neurodegeneration (both neuronal and demyelinating), osteoporosis, age-related macular degeneration and cardiovascular diseases, particularly atherosclerosis 23 .
  • the present invention relates to compounds and methods for treating diseases of aging associated with abnormal membrane cholesterol levels.
  • the described compounds include novel plasmalogen precursors which decrease membrane free cholesterol levels and augment cholesterol esterification for transport from cell membranes. These compounds therefore are useful for reducing membrane cholesterol levels in subjects suffering from elevated membrane cholesterol levels.
  • the compounds can also be used to treat or prevent diseases associated with increased membrane cholesterol such as neurodegenerative diseases (including but not limited to Alzheimer's disease, Parkinson's disease, multiple sclerosis and age-related macular degeneration), cognitive impairment, dementia, cancers (including but not limited to prostate, lung, breast, ovarian, and kidney cancer), osteoporosis, bipolar disorder and vascular diseases (including but not limited to atherosclerosis and hypercholesterolemia).
  • these compounds are useful in the treatment of disorders resulting from abnormal genetic expression of cholesterol transport proteins, such as apolipoprotein E.
  • plasmalogen precursors contain a glycerol backbone with an alkyl or alkenyl lipid substitution at sn-1 and an acyl lipid substitution at sn-2.
  • a polar substituent is provided at sn-3 to improve pharmaceutical properties (such as to improve stability and/or bioavailability, or for formulation as a salt).
  • the sn-3 substituent is cleaved by lipases and the resulting 1 -alkyl, 2-acyl glycerol or 1 -alkenyl, 2-acyl glycerol is then converted to plasmalogens in the endoplasmic reticulum, thereby bypassing the peroxisomal compartment which can demonstrate decreased function with ageing.
  • Ri and R 2 can be the same or different; and are an alkyl or alkenyl hydrocarbon chain selected from Table 1 or 2; Table 1 : Alkyl and alkenyl hydrocarbon groups
  • R 3 is a group selected from fatty acids, carnitine, acetyl-D/L-carnitine, thiocarnitine, acetyl-D/L-thiocarnitine, creatine, norcarnitine, phosphocholine, lipoic acid, dihydrolipoic acid, phosphoethanolamine, phosphoserine, N-acetylcysteine, substituted or unsubstituted amino acids and groups of the structures shown below in Table 3.
  • R 4 and R 5 are either the same or different and may be hydrogen or lower alkyl, for example methyl or ethyl;
  • R 6 is hydrogen or lower alkyl, for example methyl or ethyl
  • R 7 and Rg are either the same or different and may be hydrogen or lower alkyl, for example methyl and ethyl, and also including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
  • DHA docosahexaenoic acid
  • the compound in another embodiment, can be 2-acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)- docosa-4, 7,10, 13, 16, 19-hexaenoyloxy)-3-(hexadecyloxy)propoxy)-N,N,N-trimethyl-4- oxobutan-1-aminium.
  • the compound may be (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-I -(5-((R)- 1,2- dithiolan-3-yl)pentanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19- hexaenoate:
  • the invention also includes pharmaceutical compositions comprising PPI-1009, PPI-1011, PPI-1014, or combinations thereof.
  • certain embodiments of the compounds described herein are believed to increase plasmalogen levels and the hydrolysis of acetyl-L-carnitine from sn-3 position, and may participate in potential molecular mechanisms that include: (i) acetylation of -NH 2 and -OH functional groups in amino acids and N-terminal amino acids in peptides and proteins resulting in modification of their structure, dynamic, function and turnover; and/or (ii) acting as a molecular chaperone to larger molecules resulting in a change in the structure, molecular dynamics, and function of the larger molecule.
  • Carnitine is important in the beta oxidation of fatty acids and the acetyl moiety can be used to maintain acetyl-CoA levels.
  • Acetyl-L-carnitine (ALCAR) actions include modulation of: (i) brain energy and phospholipid metabolism; (iii) cellular macromolecules, including neurotrophic factors and hormones; (iii) synaptic morphology; and (iv) synaptic transmission of multiple neurotransmitters.
  • a method of treating or preventing diseases of aging mediated by plasmalogen deficiency comprising administering to a patient in need thereof an effective amount of a compound or composition as described above.
  • a method of treating diseases of aging associated with increased membrane cholesterol, increased amyloid and decreased plasmalogen levels comprising administering to a patient in need thereof, an effective amount of a compound or composition as described above.
  • the invention also relates to a process for preparing a compound according to the structure of formula II:
  • the blocking agent may be a silane blocking agent, for instance a tert-butyldimethylsilyl halide which then gives rise to R9 being a tert- butyldimethylsilyl group.
  • the nucleophilic catalyst may be DMAP
  • the base may be triethylamine
  • the solvent may comprise dimethylformamide (DMF) and CH 2 Cl 2 .
  • a solution including the compound of formula III, the nucleophilic catalyst, and the base in the appropriate solvent at from 0 to 5 0 C prior to addition of the blocking agent, followed by addition of the blocking agent and then carrying out the reaction at a temperature of from about 15 to about 25 0 C, for example at about 20 0 C.
  • the reaction will then preferably be allowed to proceed to completion, which may be up to 20 hours.
  • FIGURE 1 shows the general experimental procedure for preparation of PPI- 1009: 2- acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19-hexaenoyloxy)-3- (hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium, in accordance with an embodiment of the present invention.
  • FIGURE 3 shows (A) a time course of PPI- 1009 (10 ⁇ M) incorporation into plasmalogens and lack of effect on cellular levels of chimyl alcohol or the associated alkenyl-acyl-glycerol (B) of N-ReI cells (0, 6, 12, 24, 48 and 72 hr).
  • B alkenyl-acyl-glycerol
  • FIGURE 4 shows (A) the concentration-dependent (72 hr) increase of DHA plasmalogens in CHO cells with PPI-1005 and PPI- 1009. While chimyl alcohol increased DHA-plasmalogens in N-ReI cells there was no effect in CHO cells (B). Cellular plasmalogens were quantitated by LC-MS and expressed relative to CHO controls or N-ReI controls.
  • FIGURE 5 shows the concentration response for the decrease in membrane cholesterol in N- ReI cells after a 48 hr incubation with 16:0(sn-l alkyl)/DHA(sn-2 acyl) glycerol (PLM-05). Note that cholesterol levels are significantly elevated (p ⁇ 0.05) in NReI cells relative to CHO cells and that at 20 ⁇ M (PLM-05) decreases membrane free cholesterol and increases membrane cholesterol esters (p ⁇ 0.05).
  • the fatty acid substitutions at sn-2 also underwent deacylation and reacylation to form the associated plasmalogens with 20:4, 18:3, 18:2 and 18:1 at sn-2.
  • Cellular plasmalogens were quantitated by LC-MS/MS and normalized relative to N-ReI cells treated with vehicle.
  • FIGURE 7 shows that membrane cholesterol is increased in mutant N-ReI cells relative to control CHO cells.
  • Membrane cholesterol in N-ReI cells is decreased (p ⁇ 0.05) after a 48 hr incubation (20 ⁇ M) with plasmalogen precursors possessing either palmitic (16:0) or stearic (18:0) acid at sn-1 in combination with unsaturated fatty acids, particularly DHA, at sn-2.
  • free DHA was ineffective in altering membrane free cholesterol levels.
  • the diacyl analog (16:0*:DHA glycerol) was inactive.
  • PPI-1009 (16:0/DHA/ ALCAR) produced the most robust decreases in free cholesterol and augmentation of esterified cholesterol.
  • V vehicle.
  • FIGURE 8 shows the decrease (p ⁇ 0.04) in membrane cholesterol in HEK293 cells after a 48 hr incubation with 20 ⁇ M 16:0(sn-l alkyl)/DHA(sn-2 acyl) glycerol, 18:0/DHA glycerol, or 16:0/18:3 glycerol.
  • 16:0/18:1 glycerol, 16:0/18:2 glycerol, 16:0/20:4 glycerol and free DHA were ineffective in altering membrane free cholesterol levels.
  • the diacyl analog (16:0*:DHA glycerol) was inactive.
  • FIGURE 9 shows the concentration response for the decrease in membrane cholesterol in HEK293 cells after a 48 hr incubation with 16:0(sn-l alkyl)/DHA(sn-2 acyl)/acetyl-L- carnitine (sn-3 acyl) glycerol (PPI-1009).
  • FIGURE 10 shows PPI-1005 (5a, 20 ⁇ M) decreases basal and cholesterol (25.8 ⁇ M) - stimulated A ⁇ 42 secretion by HEK293 cells (A).
  • PPI-1009 (PLM09, 10 ⁇ M) acted in a similar manner (B).
  • FIGURE 11 illustrates the effect of PPI-1011 on plasmalogens in rabbit plasma.
  • PPI-IOl 1 was incorporated into plasma ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) 1, 3, 6, and 12 hours after a 200 mg/kg dose orally in a gelatin capsule.
  • FIGURE 12 shows a plot of the timecourse of incorporation of pasmalogen precursor PPI- 1011 into circulating PIs 16:0/22:6, DHA, PIs 18:0/22:6, PIs 18:1/22:6 and Ptd 16:0/22:6.
  • Incorporation of PPI-1011 in plasma ethanolamine plasmalogens (PIs) and phosphatidylethanolamines (Ptd) was measured 1, 3, 6, 12, 18, 24 and 48 hours after a 200 mg/kg dose orally in a gelatin capsule.
  • the release of DHA from sn-2, via deacylases, was also monitored. Groups consisted of 3 to 5 rabbits except the 12 hour timepoint which includes 7 rabbits from 2 separate experiments.
  • FIGURE 13 illustrates the dose-dependent incorporation of PPI-1011 into plasma plasmalogens and phosphatidylethanolamines.
  • Incorporation of PPI-1011 in plasma ethanolamine plasmalogens (PIs) and phosphatidylethanolamines (Ptd) was measured 6 hours after doses of 10, 75, 200, 500, and 1000 mg/kg orally in a gelatin capsule.
  • FIGURE 14 shows augmentation of tissue plasmalogens and DHA by PPI-1011 in rabbit kidney.
  • Incorporation of PPI-1011 in kidney ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) was measured 1, 3, 6, and 12 hours after a 200 mg/kg dose orally in a gelatin capsule.
  • FIGURE 15 shows a timecourse of the tissue plasmalogens and DHA augmentation by PPI- 1011 in rabbit kidney.
  • Incorporation of PPI-1011 in kidney ethanolamine plasmalogen (16:0/22:6) was measured 1, 3, 6, 12, 18, 24 and 48 hours after a 200 mg/kg dose orally in a gelatin capsule. Groups consisted of 3 to 5 rabbits.
  • FIGURE 16 shows a timecourse of the tissue plasmalogens and DHA augmentation by PPI- 1011 in rabbit liver. Incorporation of PPI-1011 in liver ethanolamine plasmalogen (16:0/22:6) was measured 12, 18, 24 and 48 hours after a 200 mg/kg dose orally in a gelatin capsule. Groups consisted of 3 to 5 rabbits.
  • FIGURE 17 shows structure-specific and concentration-dependent incorporation of PPI-1014 in N-ReI ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) after 72 hours (5, 10 and 20 ⁇ M). Cellular plasmalogens were quantitated by LC-MS/MS and normalized relative to N-ReI cells treated with vehicle. Groups consisted of three 10 cm 2 plates.
  • FIGURE 18 shows (A) effects of increasing PPI- 1005 concentration on membrane resident proteins in cholesterol loaded HEK293 cells, (B) effects of PPI- 1005 on membrane resident proteins in wild-type HEK293 cells, and (C) effects of pravastatin on membrane-resident proteins ADAMlO and SOATl. ⁇ -actin was used as a loading control.
  • R 3 is a group selected from fatty acids, carnitine, acetyl-D/L-carnitine, thiocarnitine, acetyl-D/L-thiocarnitine, creatine, norcarnitine, phosphocholine, lipoic acid, dihydrolipoic acid, phosphoethanolamine, phosphoserine, N-acetylcysteine, substituted or unsubstituted amino acids and groups of the structures shown below:
  • R 4 and R 5 are independently hydrogen or lower alkyl
  • R 6 is hydrogen or lower alkyl
  • R 7 and Rg are independently hydrogen or lower alkyl, and including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
  • Such compounds are useful for treating or preventing diseases of aging associated with increased membrane cholesterol, increased amyloid or decreased plasmalogen levels.
  • Such compounds are also useful for treating or preventing diseases of aging mediated by plasmalogen deficiency.
  • Such compounds can also be used to treat neurodegenerative diseases (including but not limited to Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (including but not limited to prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (including but not limited to atherosclerosis and hypercholesterolemia).
  • neurodegenerative diseases including but not limited to Alzheimer's disease, Parkinson's disease and age-related macular degeneration
  • cognitive impairment dementia
  • cancer including but not limited to prostate, lung, breast, ovarian, and kidney cancers
  • osteoporosis including but not limited to atherosclerosis and hypercholesterolemia.
  • compounds as described herein may contain one or more chiral centers.
  • such compounds will be prepared as a racemic mixture.
  • such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) of the compounds of formula I are included within the scope of this invention.
  • Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well known in the art.
  • racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
  • “Fatty acids” are aliphatic monocarboxylic acids, derived from, or contained in esterified form in an animal or vegetable fat, oil or wax. Natural fatty acids commonly have a chain of 4 to 28 carbons (usually unbranched and even numbered), which may be saturated or unsaturated. These are known as acyclic aliphatic carboxylic acids.
  • saturated fatty acids refers to carbons (apart from the initial carboxylic [-COOH] group) containing as many hydrogens as possible.
  • the omega ( ⁇ ) end contains 3 hydrogen atoms (CH 3 -), and carbon within the chain contains 2 hydrogen atoms.
  • Unsubstituted and substituted amino acids refers to an optionally substituted amino acid moiety containing an amino group, a carboxylic acid group and a variable side chain, which side chain may include common amino acid side chains, i.e., those used in forming proteins, or others as are known in the art.
  • Protein forming amino acid moieties are particularly preferred, and include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine amino acid groups. Substitutions on the amino acid moieties are also possible, including substitutions with functional groups including but not limited to lower alkyl, acetate, phosphate, lipids and carbohydrates.]
  • lower alkyl refers to a cyclic, branched or straight chain monovalent alkyl radical of one to seven carbon atoms (Ci-C 7 ), and in certain non-limiting embodiments from one to four carbon atoms (C 1 -C 4 ). This term is further exemplified by such radicals as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl (or 2-methylpropyl), cyclopropylmethyl, i-amyl, n- amyl, hexyl and heptyl. Lower alkyl groups can also be unsubstituted or substituted, where a specific example of a substituted alkyl is 1,1 -dimethyl heptyl.
  • “Hydroxyl” refers to -OH.
  • “Pharmaceutically-acceptable salt” refers to any salt of a compound of this invention which retains its biological properties and which is not biologically or otherwise undesirable. Such salts may be derived from a variety of organic and inorganic counter-ions well known in the art and include, by way of example, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • pharmaceutically- acceptable cation refers to a pharmaceutically acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.
  • “Pharmaceutically acceptable ester” refers to a conventionally esterified compound of Formula I having a carboxyl group, which esters retain the biological effectiveness and properties of the compounds of Formula I and are cleaved in vivo (in the organism) to the corresponding active carboxylic acid. Information concerning esters and the use of esters for the delivery of pharmaceutical compounds is available in Design of Prodrugs. Bundgaard H ed. (Elsevier 1985). See also, H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 108-109; Krogsgaard-Larsen, et. al. Textbook of Drug Design and Development (2d Ed. 1996) at pp. 152-191.
  • a “pharmaceutical agent” or “drug” refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
  • an effective amount means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • the compounds described herein which include plasmalogen precursors derived from a glycerol back-bone with substitution at sn-1 and sn-2 with fatty acids, and sn-3 with fatty acids or endogenous metabolic intermediate compounds, can be prepared from readily available starting materials using the following general methods and procedures shown in Figure 1. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • the choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and de-protection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
  • a preferred method of synthesis of the compounds described herein which include glycerol substitutions at sn-1 and sn-2 with fatty acids and sn-3 with fatty acids or endogenous metabolic intermediate compounds as described herein, are prepared by protection/deprotection of hydroxyl groups of the glycerol back-bone with suitable protecting groups, followed by O-alkylation and O-acylation of the compound; for example PPI- 1009, PPI-1011 and PPI-1014.
  • compositions When employed as pharmaceuticals, compounds as described herein are typically administered in the form of a pharmaceutical composition.
  • Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one active compound.
  • the compounds of this invention are administered in a pharmaceutically effective amount.
  • the amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the compounds and compositions described herein can be administered to a subject, preferably a mammal, more preferably a human, to treat and/or prevent disease by any suitable routes including, by way of illustration, oral, topical, rectal, transdermal, subcutaneous, intravenous, intramuscular, intranasal, and the like.
  • the compounds of this invention are preferably formulated as either oral, topical or injectable compositions.
  • compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, such compositions are presented in unit dosage forms to facilitate accurate dosing.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.
  • Liquid forms suitable for oral administration may include a suitable aqueous or non aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.
  • Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • Topical compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight.
  • the active ingredients When formulated as an ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example, an oil-in-water cream base.
  • Such topical formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration or stability of the active ingredients or the formulation. All such known topical formulations and ingredients are included within the scope of this invention.
  • the compounds of this invention can also be administered by a transdermal device. Accordingly, topical administration can be accomplished using a patch either of the reservoir or porous membrane type or of a solid matrix variety.
  • Injectable compositions are typically based upon injectable sterile saline or phosphate- buffered saline or other injectable carriers known in the art.
  • the alkyl nitrone compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
  • the compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems.
  • sustained release materials can be found in the incorporated materials in Remington's Pharmaceutical Sciences.
  • compositions of this invention can be formulated into tablets, capsules, liquid, injection formulation, or an ointment.
  • the present invention is not limited to the following pharmaceutical compositions.
  • the compound of formula I can be dissolved in a buffered sterile saline injectable aqueous medium to a appropriate concentration of approximately 5 mg/niL.
  • kits that can simplify the administration of a pharmaceutically active agent to an animal.
  • a typical kit of the invention comprises a unit dosage form of a pharmaceutical composition according to the invention.
  • the unit dosage form is a container (such as a vial, a pouch, a tube, a syringe, or the like), which can advantageously be sterile, containing a pharmaceutical composition of the invention.
  • the kit can further comprise a label or printed instructions instructing the use of the pharmaceutically active agent to treat or prevent a condition.
  • the kit comprises a unit dosage form of a pharmaceutical composition of the invention and a dropper, syringe, or other applicator for administering the pharmaceutical composition.
  • the components of the kit for example, the unit dosage form and instructions, are contained within a suitable packaging material.
  • bioavailable plasmalogen precursors with docosahexaenoic acid (22:6) substituition at sn-2 decreased membrane cholesterol levels.
  • stearic acid (18:0), oleic acid (18:1), linoeic acid (18:2), arachidonic acid (20:4) or linolenic (18:3), at sn-2 were much less active and free DHA was inactive.
  • the fatty acid substitution at sn-1 demonstrated an absolute requirement for an alkenyl linkage, with an acyl linkage completely eliminating cholesterol-lowering activity.
  • the alkenyl linkage can be generated in the endoplasmic reticulum from the alkyl precursor (e.g.
  • these targeted plasmalogen precursors can also be improved with the addition of a polar substituent to sn-3.
  • This substitution provides improved pharmaceutical properties including: i) stabilization of the sn-2 substitution from migration to sn-3 27"28 ii) the ability to generate a pharmaceutically- acceptable salt to improve formulation and drug dissolution and absorption; and iii) the ability of sn-3 substituents to be readily removed by lipases 29 such that the precursor can be converted to the corresponding endogenous plasmalogen.
  • administering compounds of the present invention to mammalian biological systems results in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system.
  • the elevated levels of these specific sn-2 substituted species give rise to lowering of membrane cholesterol levels and lowering of amyloid secretion, therefore making these compounds useful for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels.
  • the compounds described herein are capable of bypassing peroxisomal ether lipid biosynthesis pathways enabling both the restoration of plasmalogen levels in plasmalogen deficient subjects, as well as the delivery of pharmaceutically effective cholesterol lowering levels of specific cholesterol lowering plasmalogens. Accordingly, these molecules can be used to treat or prevent diseases associated with either decreased levels of plasmalogens, increased levels of membrane cholesterol or increased amyloid levels. These factors are believed to be causal in a wide variety of human diseases such as neurodegeneration (including without limitation
  • the present invention relates to the treatment of these diseases using the described plasmalogen precursors. Furthermore, these derivatives have utility in the treatment of disorders resulting from abnormal genetic expression of cholesterol transport proteins such as apolipoprotein E.
  • the ether bond at sn-1 is stable and is further processed by a desaturase (endoplasmic reticulum) to generate the essential alkenyl bond at sn-1 characteristic of plasmalogens but that this desaturation occurs after the addition of phosphoethanolamine by CDP- ethanolamine transferase (endoplasmic reticulum);
  • a desaturase endoplasmic reticulum
  • the fatty acid substituent at sn-2 is able to undergo deacylation and reacylation by other fatty acids in cells; 5) DHA substitution at sn-2 is optimal for lowering membrane cholesterol, and
  • the compounds of the present invention are effectively converted to PlsEtn species in cells with impaired plasmalogen biosynthesis capacity and in cells with unimpaired plasmalogen biosynthesis capacity. These results are in direct contrast to the prior art regarding other plasmalogen precursors.
  • 1-alkyl, 2-hydroxy glycerols (chimyl, batyl, salachyl alcohols) have been shown to increase PlsEtn levels in PlsEtn deficient systems to control levels but not to above control levels in either PlsEtn deficient or PlsEtn sufficient systems. Therefore, the compounds of the present invention can be useful in the prevention of diseases of the aging mediated by plasmalogen deficiency, but increasing PlsEtn levels to above control levels in either PlsEtn deficient or PlsEtn sufficient systems.
  • the compounds described herein are suitable for use in a variety of drug delivery systems; however, without wishing to be limiting, the compounds are especially useful for oral delivery in a capsule or tablet. In such embodiments the maximum total dose is not expected to exceed 2 g/day for a 40 to 80 kg human patient.
  • PPI-1009 2-acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19- hexaenoyloxy)-3 -(hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium was prepared according to the following general experimental procedure.
  • reaction mixture was quenched with water (1OmL), extracted with EtOAc (2 x 5OmL), organic layer washed with brine (2OmL), dried (Na 2 SO 4 ) and evaporated to obtain crude compound 6 that was purified by flash column chromatography (100-200 mesh silica gel, EtO Ac-Pet ether(3:7) to obtain compound 5 (850 mg, 65%) as a light yellow oil.
  • R f 0.54 (EtO Ac-Pet ether (3:7).
  • CHO Chinese hamster ovary
  • N-ReI 30 a mutant CHO cell line deficient in the peroxisomal enzyme dihydroxyacetonephosphate acyltransferase
  • human embryonic kidney a mutant CHO cell line deficient in the peroxisomal enzyme dihydroxyacetonephosphate acyltransferase
  • HEK293 cells were grown in 10 cm 2 dishes in DMEM/Ham's F12 (1 :1) containing 10% FBS. Cells were incubated with plasmalogen precursors dissolved in ethanol (final ethanol concentration of 0.1%) and harvested for plasmalogen analysis by LC-MS-MS 31 , and cholesterol and cholesterol ester analyses utilizing a commercial colorimetric kit (BioVision #K613).
  • PPI- 1009 is a plasmalogen precursor with improved pharmaceutical properties. This molecule exists at room temperatures as a salt and represents the first non-oil based plasmalogen precursor ever reported.
  • PPI- 1009 was also demonstrated to concentration-dependently decrease membrane cholesterol levels in NReI ( Figure 7) and HEK293 cells ( Figure 9). These results indicate that the membrane lowering effect of elevated PlsEtn levels requires the administration of plasmalogen precursor capable of selectively elevating PlsEtn levels with specific sn-2 substitutions.
  • PPI-1014 A structure-specific and concentration-dependent incorporation of PPI-1014 in N-ReI ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) was also observed after 72 hours using 5, 10 and 20 ⁇ M concentrations of PPI-1014 (Figure 17).
  • reaction mixture was allowed to RT and stirred for 24h.(The reaction progress was monitored by quenching small aliquots with H 2 O, extracting with ethyl acetate and spotting on an analytical silica gel TLC plate (15% THF in pet-ether), and visualizing spots using 254 nm UV light and Hanessian 's stain).
  • Reaction step Procedure: A solution of compound 1 (2.0 Kg, 15.15 mol, Alfa Aesar) in 10% NaOH solution (10.0 L) was stirred at 8O 0 C for Ih, added TBAB (992.Og, 3.03 mol, Rajdhani scientific) and stirred for 15 min. Added cetyl bromide (5.5 kg, 18.18 mol, Alfa Aesar) slowly and the reaction mixture was stirred at 8O 0 C for 2Oh.
  • TBAB 992.Og, 3.03 mol, Rajdhani scientific
  • reaction progress was monitored by diluting small aliquots with water, extracting with ethyl acetate and spotting over an analytical silica gel TLC plate (30 % Ethyl acetate in pet-ether) and visualizing respective spots using Mo stain and KMnO U solution).
  • the following are the R f S of the components of the mixture: compound 1 (0.1), compound 2 (0.7).
  • the reaction mixture was cooled to RT, extracted with CH 2 Cl 2 (3 x 3.0 L).
  • reaction progress was monitored by quenching small aliquots with water, extracting with CH2CI2 and spotting over an analytical silica gel TLC plate (20% Ethyl acetate in pet ether) and visualizing spots using Mo stain and KMn ⁇ 4 ).
  • the reaction mixture was diluted with CH 2 Cl 2 (2.0 L), washed with water (3 x 3.0 L), brine solution (1.0 L), dried over anhydrous Na 2 SO 4 and concentrated.
  • the obtained crude compound was purified by column chromatography (silica gel 100-200 mesh) using 5 % ethyl acetate in pet ether as eluent to afford compound 4 (850 g, 90%) obtained as pale yellow oil.
  • reaction mixture was diluted with ethyl acetate (2.5 L), washed with water (2 x 1.0 L), brine (1.0 L), dried over anhydrous Na 2 SO 4 and concentrated to afford crude compound, which was purified by column chromatography (silica gel 100-200 mesh) using 7 % ethyl acetate in pet ether as eluent to afford compound 6 (330 g, 48% from 2 steps) obtained as pale yellow oil.
  • reaction mixture was diluted with CH 2 Cl 2 (2.0 L), washed with brine solution (250 mL), dried over anhydrous Na 2 S ⁇ 4 and concentrated to obtain crude compound which was purified by column chromatography (silica gel 100-200 mesh) using 5 % MeOH in chloroform as eluent to afford compound 10 (153.0 g, 31.5%) obtained as pale yellow oil.
  • reaction mixture was filtered off through celite bed, washed the cake with ethanol (2 x 200 mL), the combined filtrate was concentrated to obtain crude compound, was purified by column chromatography (silica gel 100-200 mesh) using 10 % Methanol in chloroform as eluent to afford compound 11 (75 g, 60%) obtained as pale yellow oil.
  • Reaction time 17h
  • Reaction temperature O 0 C to 26 0 C
  • Triphenyl phosphene 7.5 g, 28.75 mmol
  • DIEAD 5.8g, 28.75 mmol
  • the reaction mixture was added N- Acetyl cystine (4.6 g, 28.75 mmol) and allowed to stir at RT for 16h.
  • amyloid precursor protein (APP) modulating enzyme ADAMlO and cholesterol esterification protein SOATl was observed with an increase in plasmalogen precursor concentration. Similar effects were observed in a cholesterol-loaded model. Additionally, a different APP processing enzyme, BACEl, showed a decrease in abundance only in cholesterol loaded cells. Without wishing to be bound by theory, this evidence supports a method of reducing the amyloid load in the context of Alzheimer's disease and simultaneously re-equilibrating the membrane cholesterol content of the system, thereby offering potential benefits in the treatment of diseases like atherosclerosis and hypercholesterolemia, in addition to Alzheimer's disease.
  • diseases like atherosclerosis and hypercholesterolemia in addition to Alzheimer's disease.
  • APP is predominantly processed by a canonical pathway comprised of sequential cleavage by ⁇ -secretases (encoded by presenilinl/2 genes) and ⁇ -secretase (encoded by ADAMlO).
  • This non-pathological processing of APP results in the formation of a neutotrophic peptide (sAPP ⁇ ) which exhibits protection against glutamate toxicity and hypoglycemia (Araki et al., 1991; Mattson et al., 1993; Postina et al., 2004; Fahrenholz, 2007).
  • An alternate APP processing pathway manifests itself in Alzheimer's disease, wherein APP is cleaved by ⁇ - and ⁇ -secretases in cholesterol-rich lipid rafts.
  • This "non-canonical" pathway results in the formation of A ⁇ peptides 38-43 amino acids long which tend to aggregate into plaques in the extracellular matrix, a hallmark of AD (Selkoe, 2002; Walsh et al., 2002; Selkoe, 2003; Meyer-Luehmann et al., 2008). While early-onset familial AD is explained by genetic lesions in APP or APP processing enzymes (PSEN1/2, BACE, ADAM), the underlying cause of late- onset sporadic AD (switch from non-pathogenic to pathogenic APP processing) remains unclear.
  • Elevated brain cholesterol was shown in subjects with AD (Mori et al., 2001), while rabbits fed on a cholesterol-rich diet have been shown to develop plaques in the brain (Ghribi et al., 2006).
  • In vitro data showed that plasmalogen deficient cells possess elevated free-cholesterol in the membrane, while in humans, serum-plasmalogen deficiency has been shown to correlate with a decline in cognition status (Goodenowe et al., 2007). Based on these observations, we investigated the interplay between cholesterol and plasmalogens, and identify how the balance between the two affects the pathological manifestations of AD, measured in terms of secreted A ⁇ .
  • Proposed mode of action A shift in APP processing via membrane lipid modulation
  • HEK293 Human embryonic kidney (HEK293) cells express APP and the membrane-bound machinery required to process APP, making it a good model to study APP processing.
  • Cholesterol loading of HEK293 cells increases the amount of free cholesterol by 17% (compared with Control) in the cells following a 48 hour incubation period. This elevation is accompanied with a parallel and significant increase (p ⁇ 0.05) in the A ⁇ 42 content in the conditioned medium compared with control.
  • the 65% increase in amyloid is primarily due to 22 % increase in ⁇ -secretase concentration ( Figure 18A, lane 2); the basal APP levels remain unchanged with cholesterol loading.
  • the A ⁇ 42 content in the conditioned medium dropped 70% below cholesterol-loaded levels at the 20 ⁇ M concentration (p 0.0001), while the sAPP ⁇ content in the conditioned medium was elevated.
  • the effects on APP processing do not appear to be due to a change in APP expression, rather it appears to be due to a shift in the APP processing pathway by virtue of changes in the abundance of APP processing enzymes.
  • the abundance of membrane-resident proteins can be altered in vitro by modulating the cellular plasmalogen content, which is achieved by treating cells with plasmalogen precursors as described herein.
  • HEK 293 cells cultured in DMEM, 10% FBS at 37°C, 5% CO 2 , were seeded the day before the treatment. The following day, cells membranes were loaded with exogenous cholesterol at a concentration of lO ⁇ g/ml media using methyl- ⁇ -cyclodextrin as the carrier to deliver cholesterol as described (Rong et al., 2003).
  • HEK293 cells were loaded with exogenous cholesterol as described, and treated with a PPI 1005 or with ethanol as a control.
  • Conditioned media from the treated cells was collected at the end of a 48 hour incubation period.
  • the conditioned media was enriched using Amicon ultracentrifugal filter devices (Millipore, Billerica, MA) prior to loading into the microplate.
  • ELISA was carried out as per the manufacturer's recommendations (Covance Labs, Princeton, NJ). The reactions were quenched 25 minutes after addition of the substrate, and the absorbance was read at 495nm. The experiment was carried out in triplicate. Values were calculated as pg/ml of conditioned media, and were normalized to the amount of A ⁇ detected in the conditioned media from untreated, cholesterol loaded control HEK293 cells.
  • HEK293 cells were treated as described in the amyloid assay.
  • the cell pellet was washed in PBS and lysed in a RIPA buffer containing a protease inhibitor cocktail (Sigma, St. Louis, MI). Protein in the cell lysate was quantified using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).
  • the following antibodies were used for western analyses: APP (Calbiochem, Darmstadt, Germany), BACEl and ADAMlO (Millipore, Temecula, CA), sAPP ⁇ (IBL, Gunma, Japan), SOATl (Santa Cruz Biotechnology Inc., CA), and ⁇ -actin (Sigma, St. Louis, MI).
  • Immunoprecipitation was carried out to estimate sAPP ⁇ in the conditioned medium. Briefly, antibody to sAPP ⁇ was added to conditioned media and incubated for 16 hours at 4 0 C. IP was carried out by incubating with protein A/G agarose beads for 6 hours at 4 0 C. Beads were washed with PBS and the eluted proteins were detected by immunoblotting with anti-sAPP ⁇ antibody. Band intensities were quantified using Image Processing and Analysis in Java (ImageJ) software (National Institutes of Health, Bethesda, MD) Statistical analysis
  • Kessler AR Changes in the cholesterol level, cholesterol-to- phospholipid mole ratio, and membrane lipid microviscosity in rat brain induced by age and a plant oil mixture. Biochem Pharmacol. 34: 1120-1.
  • Corrigan FM, Horrobin DF, Skinner ER, Besson JA, Cooper MB ( 1998) Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol. 30: 197-207.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Description

PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE
AGING
FIELD OF INVENTION
The present invention relates to the synthesis and utility of novel chemical entities with useful biochemical, physiochemical, and clinical properties. More specifically, a series of 1-alkyl, 2-acyl glycerol derivatives are provided which can be used for the treatment or prevention of disease. The invention also relates to pharmaceutical compositions and kits incorporating such compounds.
BACKGROUND OF THE INVENTION
It is well known that many diverse human diseases such as cancer, dementia, or decreased cognitive functioning increase in incidence with age. From an epidemiological and statistical perspective, these diseases often look very similar. However, from a clinical perspective, each of the cancers, dementias, and decreased cognitive functioning are very different. Currently, the largest risk factor for these disorders is the subject's age. Furthermore, it is well established that most cancers, dementias, and decreased cognitive functioning have a long prodromal phase (5-15 years) in which the disease is present but at a sub-clinical manifestation. Age-associated increases in membrane cholesterol1"3 and increased mitochondrial membrane cholesterol4"6 have been reported. These increases in membrane cholesterol result in decreased membrane fluidity2, decreased ion channel function6"8, decreased activities of some membrane-bound enzymes like 5 '-nucleotidase9 and α- secretase1 , and altered diffusion properties for signaling molecules like nitric oxide".
Subjects suffering from increased membrane cholesterol demonstrate an increased prevalence of neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, multiple sclerosis and age- related macular degeneration), cognitive impairment, dementia, cancers (e.g. prostate, lung, breast, ovarian, and kidney), osteoporosis, bipolar disorder and vascular diseases (atherosclerosis, hypercholesterolemia).
With respect to specific diseases, cholesterol accumulates in the brain membranes of Alzheimer's patients in a severity-dependent manner12"14. In this regard, lowering membrane cholesterol has been shown to decrease the activities of beta- and gamma-secretases, blocking the pathogenic processing of beta-amyloid15"16. At the molecular level, cholesterol binds to the transmembrane domain of amyloid precursor protein (APP), activating the trafficking of APP to cholesterol-rich membrane domains rich in beta- and gamma-secretases, resulting in amyloid-beta production17. Synaptic membrane changes resulting from increased cholesterol may also be an important factor in the utilization of membrane phospholipids to support cholinergic neurotransmission (autocannibalism concept)18. Early utilization of statins have also been suggested to reduce the incidence or delay the onset of Alzheimer's and Parkinson's diseases19. Cholesterol accumulation also occurs in the drusen associated with age-related macular degeneration20. Membrane cholesterol is also increased in cancer21 and increases in mitochondrial membrane cholesterol have been hypothesized to be the defect that leads to the Warburg effect that is associated with most cancer cells22. The Warburg effect is a defining feature of cancer cells in that, unlike normal cells, which rely almost entirely upon respiration for energy, cancer cells can utilize both respiration and glycolysis for energy.
In addition to complex negative membrane effects of cholesterol accumulation, there is also increased oxysterol production23. These oxysterols are cytotoxic (apoptosis and necrosis), pro-inflammatory, deplete GSH and induce phospholipidosis23"26. Diseases in which these toxic oxysterols might be involved include neurodegeneration (both neuronal and demyelinating), osteoporosis, age-related macular degeneration and cardiovascular diseases, particularly atherosclerosis23.
Current clinical therapies to reduce cholesterol consist mainly of inhibiting cholesterol synthesis with statins or blocking cholesterol absorption from the gastrointestinal tract with ezetimibe. To the inventors' knowledge, there are currently no drugs to mobilize cholesterol trafficking out of membranes.
SUMMARY OF THE INVENTION
The present invention relates to compounds and methods for treating diseases of aging associated with abnormal membrane cholesterol levels. The described compounds include novel plasmalogen precursors which decrease membrane free cholesterol levels and augment cholesterol esterification for transport from cell membranes. These compounds therefore are useful for reducing membrane cholesterol levels in subjects suffering from elevated membrane cholesterol levels. The compounds can also be used to treat or prevent diseases associated with increased membrane cholesterol such as neurodegenerative diseases (including but not limited to Alzheimer's disease, Parkinson's disease, multiple sclerosis and age-related macular degeneration), cognitive impairment, dementia, cancers (including but not limited to prostate, lung, breast, ovarian, and kidney cancer), osteoporosis, bipolar disorder and vascular diseases (including but not limited to atherosclerosis and hypercholesterolemia). Furthermore, these compounds are useful in the treatment of disorders resulting from abnormal genetic expression of cholesterol transport proteins, such as apolipoprotein E.
These plasmalogen precursors contain a glycerol backbone with an alkyl or alkenyl lipid substitution at sn-1 and an acyl lipid substitution at sn-2. A polar substituent is provided at sn-3 to improve pharmaceutical properties (such as to improve stability and/or bioavailability, or for formulation as a salt).
Without wishing to be bound by theory, it is believed that in certain embodiments the sn-3 substituent is cleaved by lipases and the resulting 1 -alkyl, 2-acyl glycerol or 1 -alkenyl, 2-acyl glycerol is then converted to plasmalogens in the endoplasmic reticulum, thereby bypassing the peroxisomal compartment which can demonstrate decreased function with ageing.
Accordingly, with respect to composition, there are provided compounds of formula I:
Figure imgf000004_0001
(I) wherein:
Ri and R2 can be the same or different; and are an alkyl or alkenyl hydrocarbon chain selected from Table 1 or 2; Table 1 : Alkyl and alkenyl hydrocarbon groups
No. Chemical Structure Abbr.
1 CH3(CH2)3- C4:0
2 CH3(CH2)5- C6:0
3 CH3(CH2)7- C8:0 4 CH3(CH2)9- C10:0
5 CH3(CH2)11- C12:0
6 CH3(CH2)13- C14:0
7 CH3(CH2)15- C16:0
8 CH3(CH2)17- C18:0
9 CH3(CH2)19- C20:0
10 CH3(CH2)21- C22:0
11 CH3(CH2)23- C24:0
12 CH3(CH2)3CH=CH(CH2)7- C14:l
13 CH3(CH2)5CH=CH(CH2)7- C16:l
14 CH3(CH2)7CH=CH(CH2)7- C18:l
15 CH3(CH2)4CH=CHCH2CH=CH(CH2)7- C18:2
16 CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)7- C18:3
17 CH3CH2(CH=CH)- C4:l
18 CH3(CH2)3(CH=CH)- C6:l
19 CH3(CH2)5(CH=CH)- C8:l
20 CH3(CH2)7(CH=CH)- C10:l
21 CH3(CH2)9(CH-CH)- C12:l
22 CH3(CH2) 11 (CH=CH)- C14:l
23 CH3(CH2)13(CH=CH)- C16:l
24 CH3(CH2)15(CH=CH)- C18:l
25 CH3(CH2)17(CH=CH)- C20:l
26 CH3(CH2) 19(CH=CH)- C22:l
27 CH3(CH2)21 (CH=CH)- C24:l
28 CH3(CH2)3CH=CH(CH2)5(CH=CH)- C14:2
29 CH3(CH2)5CH=CH(CH2)5(CH=CH)- C16:2
30 CH3(CH2)7CH=CH(CH2)5(CH=CH)- C18:2
31 CH3(CH2)4CH=CHCH2CH=CH(CH2)5(CH=CH)- C18:3
32 CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)5(CH=CH)- C18:4
Table 2: Unsaturated cis fatty acid side chains
No. Name of acid Chemical Structure
1 Myristoleic (14:1) CH3(CH2)3CH=CH(CH2)7-
2 Palmitoleic (16:l) CH3(CH2)5CH=CH(CH2)7-
3 Oleic (18:1) CH3(CH2)7CH=CH(CH2)7-
4 Linoleic (18:2) CH3(CH2)4(CH=CHCH2)2(CH2)6-
5 Linolenic (18:3) CH3CH2(CH=CHCH2)3(CH2)6-
6 Arachidonic (20:4) CH3(CH2)4(CH=CHCH2)4(CH2)2-
7 Eicosapentaenoic (20:5) CH3CH2(CH=CHCH2)5(CH2)2-
8 Erucic (22:1) CH3(CH2)7CH=CH(CH2)i i-
9 Docosahexaenoic (22:6) CH3CH2(CH=CHCH2)6CH2-
R3 is a group selected from fatty acids, carnitine, acetyl-D/L-carnitine, thiocarnitine, acetyl-D/L-thiocarnitine, creatine, norcarnitine, phosphocholine, lipoic acid, dihydrolipoic acid, phosphoethanolamine, phosphoserine, N-acetylcysteine, substituted or unsubstituted amino acids and groups of the structures shown below in Table 3. Table 3
Figure imgf000006_0001
R4 and R5 are either the same or different and may be hydrogen or lower alkyl, for example methyl or ethyl;
R6 is hydrogen or lower alkyl, for example methyl or ethyl; and
R7 and Rg are either the same or different and may be hydrogen or lower alkyl, for example methyl and ethyl, and also including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
Another aspect of this invention is directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound as described above. In one embodiment of the present invention R2 may be a docosahexaenoic acid (DHA) side chain, or CH3CH2(CH=CHCH2)6CH2-.
In another embodiment, the compound can be 2-acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)- docosa-4, 7,10, 13, 16, 19-hexaenoyloxy)-3-(hexadecyloxy)propoxy)-N,N,N-trimethyl-4- oxobutan-1-aminium.
Figure imgf000007_0001
PPI-1009
In other embodiments the compound may be (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-I -(5-((R)- 1,2- dithiolan-3-yl)pentanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19- hexaenoate:
Figure imgf000007_0002
PPI-1011 or (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(2-acetamido-3-mercaptopropanoyloxy)-3- (hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate:
Figure imgf000007_0003
PPI-1014.
The invention also includes pharmaceutical compositions comprising PPI-1009, PPI-1011, PPI-1014, or combinations thereof. Without wishing to be bound by theory, certain embodiments of the compounds described herein are believed to increase plasmalogen levels and the hydrolysis of acetyl-L-carnitine from sn-3 position, and may participate in potential molecular mechanisms that include: (i) acetylation of -NH2 and -OH functional groups in amino acids and N-terminal amino acids in peptides and proteins resulting in modification of their structure, dynamic, function and turnover; and/or (ii) acting as a molecular chaperone to larger molecules resulting in a change in the structure, molecular dynamics, and function of the larger molecule.
Carnitine is important in the beta oxidation of fatty acids and the acetyl moiety can be used to maintain acetyl-CoA levels. Acetyl-L-carnitine (ALCAR) actions include modulation of: (i) brain energy and phospholipid metabolism; (iii) cellular macromolecules, including neurotrophic factors and hormones; (iii) synaptic morphology; and (iv) synaptic transmission of multiple neurotransmitters.
According to a further aspect of the present invention there is provided a method of treating or preventing diseases of aging mediated by plasmalogen deficiency, comprising administering to a patient in need thereof an effective amount of a compound or composition as described above.
In a further aspect of the present invention there is provided a method of treating diseases of aging associated with increased membrane cholesterol, increased amyloid and decreased plasmalogen levels comprising administering to a patient in need thereof, an effective amount of a compound or composition as described above.
The invention also relates to a process for preparing a compound according to the structure of formula II:
Figure imgf000008_0001
(H) wherein Ri and R4 to R8 are as described above and R9 is a blocking group, and including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof. The process involves reacting a compound of formula III:
Figure imgf000009_0001
(III) in a suitable solvent with a nucleophilic catalyst, a base and a blocking agent under conditions to form said compound of formula II, and optionally purifying the resulting compound.
In certain non-limiting embodiments the blocking agent may be a silane blocking agent, for instance a tert-butyldimethylsilyl halide which then gives rise to R9 being a tert- butyldimethylsilyl group.
In other non-limiting embodiments the nucleophilic catalyst may be DMAP, the base may be triethylamine, and the solvent may comprise dimethylformamide (DMF) and CH2Cl2.
Without wishing to be limiting, it may in certain embodiments be preferred to prepare a solution including the compound of formula III, the nucleophilic catalyst, and the base in the appropriate solvent at from 0 to 5 0C prior to addition of the blocking agent, followed by addition of the blocking agent and then carrying out the reaction at a temperature of from about 15 to about 25 0C, for example at about 20 0C. The reaction will then preferably be allowed to proceed to completion, which may be up to 20 hours.
Also provided is an intermediate compound according to the structure of formula II:
Figure imgf000009_0002
(H) wherein R1 and R4 to R9 are as described above, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:
FIGURE 1 shows the general experimental procedure for preparation of PPI- 1009: 2- acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19-hexaenoyloxy)-3- (hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium, in accordance with an embodiment of the present invention.
FIGURE 2 shows decreased levels of total DHA plasmalogens in N-ReI cells, relative to control CHO cells, are restored in a concentration-dependent manner by PPI-1005 (Ri= 16:0; R2=DHA; R3=OH). 72 hr incubation. * p <0/05 vs. vehicle (veh).
FIGURE 3 shows (A) a time course of PPI- 1009 (10 μM) incorporation into plasmalogens and lack of effect on cellular levels of chimyl alcohol or the associated alkenyl-acyl-glycerol (B) of N-ReI cells (0, 6, 12, 24, 48 and 72 hr). Cellular plasmalogens and docosahexaenoic (DHA) acid were quantitated by LC-MS/MS while chimyl alcohol was quantitated by GC- MS.
FIGURE 4 shows (A) the concentration-dependent (72 hr) increase of DHA plasmalogens in CHO cells with PPI-1005 and PPI- 1009. While chimyl alcohol increased DHA-plasmalogens in N-ReI cells there was no effect in CHO cells (B). Cellular plasmalogens were quantitated by LC-MS and expressed relative to CHO controls or N-ReI controls.
FIGURE 5 shows the concentration response for the decrease in membrane cholesterol in N- ReI cells after a 48 hr incubation with 16:0(sn-l alkyl)/DHA(sn-2 acyl) glycerol (PLM-05). Note that cholesterol levels are significantly elevated (p < 0.05) in NReI cells relative to CHO cells and that at 20 μM (PLM-05) decreases membrane free cholesterol and increases membrane cholesterol esters (p < 0.05). FIGURE 6 shows structure-specific and concentration-dependent incorporation (72 hr) into the associated plasmalogen (Ri=I 6:0, R2=22:6, R3=phosphoethanolamine) of N-ReI cells with PPI-1005 (A; 1 and 5 μM) and PPI-1009 (B; 0.5, 1, 2, 3 & 10 μM). The fatty acid substitutions at sn-2 also underwent deacylation and reacylation to form the associated plasmalogens with 20:4, 18:3, 18:2 and 18:1 at sn-2. Cellular plasmalogens were quantitated by LC-MS/MS and normalized relative to N-ReI cells treated with vehicle.
FIGURE 7 shows that membrane cholesterol is increased in mutant N-ReI cells relative to control CHO cells. Membrane cholesterol in N-ReI cells is decreased (p<0.05) after a 48 hr incubation (20 μM) with plasmalogen precursors possessing either palmitic (16:0) or stearic (18:0) acid at sn-1 in combination with unsaturated fatty acids, particularly DHA, at sn-2. At 20 μM, free DHA was ineffective in altering membrane free cholesterol levels. In contrast to the activity of analogs with an alkyl linkage at sn-1, the diacyl analog (16:0*:DHA glycerol) was inactive. PPI-1009 (16:0/DHA/ ALCAR) produced the most robust decreases in free cholesterol and augmentation of esterified cholesterol. V, vehicle.
FIGURE 8 shows the decrease (p < 0.04) in membrane cholesterol in HEK293 cells after a 48 hr incubation with 20 μM 16:0(sn-l alkyl)/DHA(sn-2 acyl) glycerol, 18:0/DHA glycerol, or 16:0/18:3 glycerol. At 20 μM, 16:0/18:1 glycerol, 16:0/18:2 glycerol, 16:0/20:4 glycerol and free DHA were ineffective in altering membrane free cholesterol levels. In contrast to the activity of analogs with an alkyl linkage at sn-1, the diacyl analog (16:0*:DHA glycerol) was inactive.
FIGURE 9 shows the concentration response for the decrease in membrane cholesterol in HEK293 cells after a 48 hr incubation with 16:0(sn-l alkyl)/DHA(sn-2 acyl)/acetyl-L- carnitine (sn-3 acyl) glycerol (PPI-1009).
FIGURE 10 shows PPI-1005 (5a, 20 μM) decreases basal and cholesterol (25.8 μM) - stimulated Aβ42 secretion by HEK293 cells (A). PPI-1009 (PLM09, 10 μM) acted in a similar manner (B). FIGURE 11 illustrates the effect of PPI-1011 on plasmalogens in rabbit plasma. PPI-IOl 1 was incorporated into plasma ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) 1, 3, 6, and 12 hours after a 200 mg/kg dose orally in a gelatin capsule. The release of DHA (free 22:6) from sn-2, via deacylases, was also monitored. Groups consisted of 3 to 5 rabbits.
FIGURE 12 shows a plot of the timecourse of incorporation of pasmalogen precursor PPI- 1011 into circulating PIs 16:0/22:6, DHA, PIs 18:0/22:6, PIs 18:1/22:6 and Ptd 16:0/22:6. Incorporation of PPI-1011 in plasma ethanolamine plasmalogens (PIs) and phosphatidylethanolamines (Ptd) was measured 1, 3, 6, 12, 18, 24 and 48 hours after a 200 mg/kg dose orally in a gelatin capsule. The release of DHA from sn-2, via deacylases, was also monitored. Groups consisted of 3 to 5 rabbits except the 12 hour timepoint which includes 7 rabbits from 2 separate experiments.
FIGURE 13 illustrates the dose-dependent incorporation of PPI-1011 into plasma plasmalogens and phosphatidylethanolamines. Incorporation of PPI-1011 in plasma ethanolamine plasmalogens (PIs) and phosphatidylethanolamines (Ptd) was measured 6 hours after doses of 10, 75, 200, 500, and 1000 mg/kg orally in a gelatin capsule. The release of DHA from sn-2, via deacylases, was also monitored. Groups consisted of 3 to 5 rabbits.
FIGURE 14 shows augmentation of tissue plasmalogens and DHA by PPI-1011 in rabbit kidney. Incorporation of PPI-1011 in kidney ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) was measured 1, 3, 6, and 12 hours after a 200 mg/kg dose orally in a gelatin capsule. The release of DHA (free 22:6) from sn-2, via deacylases, was also monitored. Groups consisted of 3 to 5 rabbits.
FIGURE 15 shows a timecourse of the tissue plasmalogens and DHA augmentation by PPI- 1011 in rabbit kidney. Incorporation of PPI-1011 in kidney ethanolamine plasmalogen (16:0/22:6) was measured 1, 3, 6, 12, 18, 24 and 48 hours after a 200 mg/kg dose orally in a gelatin capsule. Groups consisted of 3 to 5 rabbits.
FIGURE 16 shows a timecourse of the tissue plasmalogens and DHA augmentation by PPI- 1011 in rabbit liver. Incorporation of PPI-1011 in liver ethanolamine plasmalogen (16:0/22:6) was measured 12, 18, 24 and 48 hours after a 200 mg/kg dose orally in a gelatin capsule. Groups consisted of 3 to 5 rabbits. FIGURE 17 shows structure-specific and concentration-dependent incorporation of PPI-1014 in N-ReI ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) after 72 hours (5, 10 and 20 μM). Cellular plasmalogens were quantitated by LC-MS/MS and normalized relative to N-ReI cells treated with vehicle. Groups consisted of three 10 cm2 plates.
FIGURE 18 shows (A) effects of increasing PPI- 1005 concentration on membrane resident proteins in cholesterol loaded HEK293 cells, (B) effects of PPI- 1005 on membrane resident proteins in wild-type HEK293 cells, and (C) effects of pravastatin on membrane-resident proteins ADAMlO and SOATl. β-actin was used as a loading control.
DETAILED DESCRIPTION
Described herein are compounds according to structure of formula I:
Figure imgf000013_0001
(i) wherein: Ri and R2 are the same or different and selected from an alkyl or alkenyl hydrocarbon chain selected from the group consisting of: CH3(CH2)3-, CH3(CH2)5-, CH3(CH2)7-, CH3(CH2)9-, CH3(CH2)11-, CH3(CH2)13-, CH3(CH2)15-, CH3(CH2)17-, CH3(CH2)19-, CH3(CH2)21-, CH3(CH2)23-, CH3(CH2)3CH=CH(CH2)7-, CH3(CH2)5CH=CH(CH2)7-, CH3(CH2)7CH=CH(CH2)7-, CH3(CH2)4CH=CHCH2CH=CH(CH2)7-, CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)7-, CH3CH2(CH=CH)-, CH3(CH2)3(CH=CH)-, CH3(CH2)5(CH=CH)-, CH3(CH2)7(CH=CH)-, CH3(CH2)9(CH=CH)-, CH3(CH2)11(CH=CH)-, CH3(CH2)13(CH=CH)-, CH3(CH2)15(CH=CH)-, CH3(CH2)17(CH=CH)-, CH3(CH2)19(CH=CH)-, CH3(CH2)21 (CH=CH)-, CH3(CH2)3CH=CH(CH2)5(CH=CH)-, CH3(CH2)5CH=CH(CH2)5(CH=CH)-, CH3(CH2)7CH=CH(CH2)5(CH=CH)-, CH3(CH2)4CH=CHCH2CH=CH(CH2)5(CH=CH), CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)5(CH=CH)-, CH3(CH2)3CH=CH(CH2)7-, CH3(CH2)5CH=CH(CH2)7-, CH3(CH2)7CH=CH(CH2)7-, CH3(CH2)4(CH=CHCH2)2(CH2)6-, CH3CH2(CH=CHCH2)3(CH2)6-, CH3(CH2)4(CH=CHCH2)4(CH2)2-, CH3CH2(CH=CHCH2)5(CH2)2-, CH3(CH2)7CH=CH(CH2)π, and CH3CH2(CH=CHCH2)6CH2-
R3 is a group selected from fatty acids, carnitine, acetyl-D/L-carnitine, thiocarnitine, acetyl-D/L-thiocarnitine, creatine, norcarnitine, phosphocholine, lipoic acid, dihydrolipoic acid, phosphoethanolamine, phosphoserine, N-acetylcysteine, substituted or unsubstituted amino acids and groups of the structures shown below:
Figure imgf000014_0001
R4 and R5 are independently hydrogen or lower alkyl;
R6 is hydrogen or lower alkyl; and
R7 and Rg are independently hydrogen or lower alkyl, and including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
Such compounds are useful for treating or preventing diseases of aging associated with increased membrane cholesterol, increased amyloid or decreased plasmalogen levels.
Such compounds are also useful for treating or preventing diseases of aging mediated by plasmalogen deficiency.
Such compounds can also be used to treat neurodegenerative diseases (including but not limited to Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (including but not limited to prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (including but not limited to atherosclerosis and hypercholesterolemia).
For the purposes of this invention, the hydroxy groups at the sn-1, sn-2, and sn-3 positions of the glycerol back -bone of the compounds of formula I are named using conventional plasmalogen nomenclature, i.e., the oxygen atom of the glycerol bonded to the carbonyl group -C=O(acetyl), -C (form ether bond) and -P (Phosphoryl) is designated in the formula I.
In certain non-limiting embodiments, compounds as described herein may contain one or more chiral centers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) of the compounds of formula I are included within the scope of this invention. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
Definitions:
When describing the alkyl/acyl fatty acids (Table 1 , Table 2) and biologically active compounds (Table 3), pharmaceutical compositions and methods of this invention, the following terms have the following meanings unless otherwise specified.
"Fatty acids" are aliphatic monocarboxylic acids, derived from, or contained in esterified form in an animal or vegetable fat, oil or wax. Natural fatty acids commonly have a chain of 4 to 28 carbons (usually unbranched and even numbered), which may be saturated or unsaturated. These are known as acyclic aliphatic carboxylic acids.
Within the meaning of saturated fatty acids, the term "saturated" refers to carbons (apart from the initial carboxylic [-COOH] group) containing as many hydrogens as possible. In other words, the omega (ω) end contains 3 hydrogen atoms (CH3-), and carbon within the chain contains 2 hydrogen atoms.
Unsaturated fatty acids (including but not limited to the examples described in Table 2) are of similar form to saturated fatty acids, except that one or more alkenyl functional groups exist along the chain, with each alkene substituting a single bonded -CH2-CH2- part of the chain with a double-bonded -CH=CH- portion (that is a carbon double-bonded to another carbon). These are named as CIS/TRANS and C:D where C is known as number of carbon atoms and D known as double bond.
"Unsubstituted and substituted amino acids" refers to an optionally substituted amino acid moiety containing an amino group, a carboxylic acid group and a variable side chain, which side chain may include common amino acid side chains, i.e., those used in forming proteins, or others as are known in the art. Protein forming amino acid moieties are particularly preferred, and include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine amino acid groups. Substitutions on the amino acid moieties are also possible, including substitutions with functional groups including but not limited to lower alkyl, acetate, phosphate, lipids and carbohydrates.]
The term "lower alkyl" refers to a cyclic, branched or straight chain monovalent alkyl radical of one to seven carbon atoms (Ci-C7), and in certain non-limiting embodiments from one to four carbon atoms (C1-C4). This term is further exemplified by such radicals as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl (or 2-methylpropyl), cyclopropylmethyl, i-amyl, n- amyl, hexyl and heptyl. Lower alkyl groups can also be unsubstituted or substituted, where a specific example of a substituted alkyl is 1,1 -dimethyl heptyl.
"Hydroxyl" refers to -OH. "Pharmaceutically-acceptable salt" refers to any salt of a compound of this invention which retains its biological properties and which is not biologically or otherwise undesirable. Such salts may be derived from a variety of organic and inorganic counter-ions well known in the art and include, by way of example, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. The term "pharmaceutically- acceptable cation" refers to a pharmaceutically acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.
"Pharmaceutically acceptable ester" refers to a conventionally esterified compound of Formula I having a carboxyl group, which esters retain the biological effectiveness and properties of the compounds of Formula I and are cleaved in vivo (in the organism) to the corresponding active carboxylic acid. Information concerning esters and the use of esters for the delivery of pharmaceutical compounds is available in Design of Prodrugs. Bundgaard H ed. (Elsevier 1985). See also, H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 108-109; Krogsgaard-Larsen, et. al. Textbook of Drug Design and Development (2d Ed. 1996) at pp. 152-191.
A "pharmaceutical agent" or "drug" refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
The term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
All chemical compounds include both the (+) and (-) stereoisomers, as well as either the (+) or (-) stereoisomer.
Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (1985) and The Condensed Chemical Dictionary (1981).
The compounds described herein, which include plasmalogen precursors derived from a glycerol back-bone with substitution at sn-1 and sn-2 with fatty acids, and sn-3 with fatty acids or endogenous metabolic intermediate compounds, can be prepared from readily available starting materials using the following general methods and procedures shown in Figure 1. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and de-protection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
In a preferred method of synthesis of the compounds described herein, which include glycerol substitutions at sn-1 and sn-2 with fatty acids and sn-3 with fatty acids or endogenous metabolic intermediate compounds as described herein, are prepared by protection/deprotection of hydroxyl groups of the glycerol back-bone with suitable protecting groups, followed by O-alkylation and O-acylation of the compound; for example PPI- 1009, PPI-1011 and PPI-1014.
When employed as pharmaceuticals, compounds as described herein are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one active compound.
Generally the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
The compounds and compositions described herein can be administered to a subject, preferably a mammal, more preferably a human, to treat and/or prevent disease by any suitable routes including, by way of illustration, oral, topical, rectal, transdermal, subcutaneous, intravenous, intramuscular, intranasal, and the like. Depending on the intended route of delivery, the compounds of this invention are preferably formulated as either oral, topical or injectable compositions.
Pharmaceutical compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, such compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.
Liquid forms suitable for oral administration may include a suitable aqueous or non aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
Topical compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example, an oil-in-water cream base. Such topical formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration or stability of the active ingredients or the formulation. All such known topical formulations and ingredients are included within the scope of this invention.
The compounds of this invention can also be administered by a transdermal device. Accordingly, topical administration can be accomplished using a patch either of the reservoir or porous membrane type or of a solid matrix variety.
Injectable compositions are typically based upon injectable sterile saline or phosphate- buffered saline or other injectable carriers known in the art. As before, the alkyl nitrone compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
The above-described components for orally and topically administrable or injectable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's Pharmaceutical Sciences, 18th edition, 1990, Mack Publishing Company, Easton, Pennsylvania, 18042, which is incorporated herein by reference.
The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in the incorporated materials in Remington's Pharmaceutical Sciences.
The pharmaceutical compositions of this invention can be formulated into tablets, capsules, liquid, injection formulation, or an ointment. The present invention, however, is not limited to the following pharmaceutical compositions. For example, yet without wishing to be limiting in any way, the compound of formula I can be dissolved in a buffered sterile saline injectable aqueous medium to a appropriate concentration of approximately 5 mg/niL.
The invention also encompasses kits that can simplify the administration of a pharmaceutically active agent to an animal. A typical kit of the invention comprises a unit dosage form of a pharmaceutical composition according to the invention. In one embodiment, the unit dosage form is a container (such as a vial, a pouch, a tube, a syringe, or the like), which can advantageously be sterile, containing a pharmaceutical composition of the invention. The kit can further comprise a label or printed instructions instructing the use of the pharmaceutically active agent to treat or prevent a condition. In another embodiment, the kit comprises a unit dosage form of a pharmaceutical composition of the invention and a dropper, syringe, or other applicator for administering the pharmaceutical composition.
Typically, the components of the kit, for example, the unit dosage form and instructions, are contained within a suitable packaging material.
Herein it is shown that bioavailable plasmalogen precursors with docosahexaenoic acid (22:6) substituition at sn-2 decreased membrane cholesterol levels. In contrast, stearic acid (18:0), oleic acid (18:1), linoeic acid (18:2), arachidonic acid (20:4) or linolenic (18:3), at sn-2, were much less active and free DHA was inactive. The fatty acid substitution at sn-1 demonstrated an absolute requirement for an alkenyl linkage, with an acyl linkage completely eliminating cholesterol-lowering activity. The alkenyl linkage can be generated in the endoplasmic reticulum from the alkyl precursor (e.g. PPI- 1009); however, the synthetic alkenyl form could also be a potential therapeutic molecule. The pharmaceutical properties of these targeted plasmalogen precursors can also be improved with the addition of a polar substituent to sn-3. This substitution provides improved pharmaceutical properties including: i) stabilization of the sn-2 substitution from migration to sn-327"28 ii) the ability to generate a pharmaceutically- acceptable salt to improve formulation and drug dissolution and absorption; and iii) the ability of sn-3 substituents to be readily removed by lipases29 such that the precursor can be converted to the corresponding endogenous plasmalogen.
Accordingly, administering compounds of the present invention to mammalian biological systems results in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. The elevated levels of these specific sn-2 substituted species give rise to lowering of membrane cholesterol levels and lowering of amyloid secretion, therefore making these compounds useful for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels.
Without wishing to be bound by theory, it is believed that the compounds described herein are capable of bypassing peroxisomal ether lipid biosynthesis pathways enabling both the restoration of plasmalogen levels in plasmalogen deficient subjects, as well as the delivery of pharmaceutically effective cholesterol lowering levels of specific cholesterol lowering plasmalogens. Accordingly, these molecules can be used to treat or prevent diseases associated with either decreased levels of plasmalogens, increased levels of membrane cholesterol or increased amyloid levels. These factors are believed to be causal in a wide variety of human diseases such as neurodegeneration (including without limitation
Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (including without limitation prostate, lung, breast, ovarian, and kidney cancer), osteoporosis, bipolar disorder and vascular diseases (including but not limited to atherosclerosis and hypercholesterolemia). Accordingly, the present invention relates to the treatment of these diseases using the described plasmalogen precursors. Furthermore, these derivatives have utility in the treatment of disorders resulting from abnormal genetic expression of cholesterol transport proteins such as apolipoprotein E.
It is also shown herein that the administration of 1 -alkyl-2-alkyl glycerols result in the stereoselective elevation of PlsEtn levels in both PlsEtn normal and PlsEtn deficient systems. These data also demonstrate for the first time that 1-alkyl, 2-acylglycerols reduce membrane cholesterol levels and amyloid levels and that these effects require specific fatty acid substitutions at the sn-2 position.
The inventors also demonstrate herein that:
1) the ether bond at sn-1 is stable and is further processed by a desaturase (endoplasmic reticulum) to generate the essential alkenyl bond at sn-1 characteristic of plasmalogens but that this desaturation occurs after the addition of phosphoethanolamine by CDP- ethanolamine transferase (endoplasmic reticulum);
2) the charged substitution at sn-3 stabilizes the fatty acid substitution at sn-2 from migrating27'28 to sn-3;
3) the charged substitution at sn-3 is readily cleaved by cellular lipases and provides the free hydroxyl group for the addition of phosphoethanolamine by CDP-ethanolamine transferase (endoplasmic reticulum);
4) the fatty acid substituent at sn-2 is able to undergo deacylation and reacylation by other fatty acids in cells; 5) DHA substitution at sn-2 is optimal for lowering membrane cholesterol, and
6) the charged substitution at sn-3 improves the pharmaceutical properties (stability, bioavailability and formulation as a salt) of the novel presented plasmalogen precursors.
The compounds of the present invention are effectively converted to PlsEtn species in cells with impaired plasmalogen biosynthesis capacity and in cells with unimpaired plasmalogen biosynthesis capacity. These results are in direct contrast to the prior art regarding other plasmalogen precursors. 1-alkyl, 2-hydroxy glycerols (chimyl, batyl, salachyl alcohols) have been shown to increase PlsEtn levels in PlsEtn deficient systems to control levels but not to above control levels in either PlsEtn deficient or PlsEtn sufficient systems. Therefore, the compounds of the present invention can be useful in the prevention of diseases of the aging mediated by plasmalogen deficiency, but increasing PlsEtn levels to above control levels in either PlsEtn deficient or PlsEtn sufficient systems.
As discussed above, the compounds described herein are suitable for use in a variety of drug delivery systems; however, without wishing to be limiting, the compounds are especially useful for oral delivery in a capsule or tablet. In such embodiments the maximum total dose is not expected to exceed 2 g/day for a 40 to 80 kg human patient.
In the following examples the following abbreviations have the following meanings. Abbreviations not defined below have their generally accepted meaning.
bd = broad doublet bs = broad singlet d = doublet dd = doublet of doublets dec = decomposed dH2O = distilled water
ELISA = enzyme-linked immuno-sorbent assay
EtOAc = ethyl acetate
EtOH = ethanol g = grams h = hours
Hz = hertz ip = intraperitoneal
L liter m = multiplet min = minutes
M = molar
M MeeOOHH == mmeetthhaannooll mg milligram
MHz megahertz niL = milliliter mmol = millimole m.p. = melting point
N normal po per os, oral q quartet quint. = quintet s = singlet t triplet
THF tetrahydrofuran tic thin layer chromatography μg microgram μL microliter
UV ultraviolet
In the examples below, all temperatures are in degrees Celsius unless otherwise indicated.
The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention.
EXAMPLES
EXAMPLE 1: Chemical Synthesis
PPI-1009: 2-acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19- hexaenoyloxy)-3 -(hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium was prepared according to the following general experimental procedure.
Step -1
At 0 °C, to a solution of unlabelled PPI-1001 (50 g, 158 mmol) in dry DMF (20 mL), was added imidazole (21.5 g, 316 mmol), the resulting mixture stirred for 10 min. A solution of TBDMS-Cl (26.2 g, 174 mmol) in DMF (5OmL) was added drop wise and the resulting solution was stirred at rt for 4 h. The reaction mixture was diluted with water (50ml), extracted with EtOAc (2 x 25OmL). The organic layer washed with ice water (2 x 10OmL), brine (5OmL), dried (Na2SC^) and evaporated to obtain crude compound 4 that was purified by column chromatography (neutral alumina, EtO Ac-Pet ether (0.5:9.5) to obtain compound 3 (45 g, 66%). Rf= 0.65 (EtO Ac-Pet ether (1-9)) Step-2
At 0 0C, to a solution of compound 3 (75 g, 174 mmol) in DMF (75OmL) NaH (60% dispersion in oil, 5g, 209 mmol) was added portion wise, stirred for 30 min, benzyl bromide (44.8g, 262 mmol) added drop wise over a period of Ih, slowly allowed to rt and stirred overnight until complete consumption of compound 3 as evidenced by tic analysis. The reaction mixture was cooled to 0 0C, methanol (5mL), ice cold water (5OmL) added, extracted with Et2O (2 x 25OmL), organic layer washed with water (2 x 5OmL), brine (5OmL), dried (Na2SO4) and evaporated to obtain crude compound 4 (90 g) as yellow oil (Rf= 0.7; EtO Ac- Pet ether [5-95]), that was used as such for the next step without further purification.
Step-3
At -15 °C, to a solution of compound 4 (1.7 g, 3.26 mmol) in dry THF (15 mL), a solution of TBAF (1.7 g, 6.53 mmol) in dry THF (5mL) added and the reaction mixture slowly warmed to rt and stirred overnight until complete consumption of compound 4 as evidenced by tic analysis. The reaction mixture was quenched with water (1OmL), extracted with EtOAc (2 x 5OmL), organic layer washed with brine (2OmL), dried (Na2SO4) and evaporated to obtain crude compound 6 that was purified by flash column chromatography (100-200 mesh silica gel, EtO Ac-Pet ether(3:7) to obtain compound 5 (850 mg, 65%) as a light yellow oil. Rf= 0.54 (EtO Ac-Pet ether (3:7).
Step-4
At 0 °C, to a solution of compound 7 (8g, 39 mmol) in dry CH2Cl2(50mL)-DMF (3 drops) oxalyl chloride (4.2 mL, 40 mmol) was added and resulting mixture slowly warmed to rt stirred for 5 h. Excess oxalyl chloride was evaporated and residue dissolved in toluene and solvent evaporated to obtain compound 6. A solution of compound 6 in dry CH2Cl2 (25mL) was added dropwise to a solution of compound 5 (1 Ig, 20mmol) in dry CH2Cl2 (5OmL) and the resulting solution purged with Argon gas till complete consumption of compound 5 as evidenced by tic analysis. The reaction mixture was concentrated to obtain crude compound 8 (14g) that was used as such for the next step without further purification.. Rf= 0.45 (MeOH- CHCl3 (1 :4)).
Step-5 A solution of compound 8 (14g crude) in EtOH (50 mL), was hydrogenated over 10% Pd/C at 40psi, until complete consumption of compound 8 as indicated by TLC analysis. The reaction mixture was filtered and evaporated to obtain crude compound 9, which was purified by column chromatography over neutral alumina to give compound 9 (6g, 6g, 61% over two steps) as a light brown oil Rf= 0.25 (MeOH-CHCl3 (2:3)).
Step-6
At 0 0C, to a solution of compound 9 (8.2 mg, 16 mmol) in THF (15OmL), catalytic amount of DMAP (1.9g, 20 mmol), pyridine (7.6 mL, 90 mmol) were added and stirred at rt for an hour. To this solution, a solution of DHA-Cl (prepared by addition of a solution of oxalyl chloride (2.5 mL, 28 mmol) in dry CH2Cl2 at 0 0C to DHA-acid (7.7g, 20 mmol), evaporating excess oxalyl chloride to give DHA-Cl) in CH2Cl2 (5OmL) was added drop wise to the reaction mixture at 0 °C and stirred for 0.5 h. The reaction mixture was slowly warmed to rt and stirred for 24 h. The reaction mixture was diluted with water (5OmL), extracted with EtOAc (2 x 20OmL), washed with brine (5OmL) dried (Na2SO4) and evaporated to obtain crude that was purified by column chromatography (neutral alumina MeOH-CHCl3(5 :95)) to obtain PPI-1009 (1.2g, -10%, HPLC purity 97% along with 1.7g of impure material) as a light brown semisolid Rf= 0.45 ( MeOH-CHCl3 (15:85)).
EXAMPLE 2: Biological Testing
Chinese hamster ovary (CHO), N-ReI30 (a mutant CHO cell line deficient in the peroxisomal enzyme dihydroxyacetonephosphate acyltransferase), and human embryonic kidney
(HEK293) cells were grown in 10 cm2 dishes in DMEM/Ham's F12 (1 :1) containing 10% FBS. Cells were incubated with plasmalogen precursors dissolved in ethanol (final ethanol concentration of 0.1%) and harvested for plasmalogen analysis by LC-MS-MS31, and cholesterol and cholesterol ester analyses utilizing a commercial colorimetric kit (BioVision #K613).
1-alkyl, 2-acyl glycerols with 16:0 at sn-1, DHA at sn-2 and either OH or acetyl-L-carnitine at sn-3, PPI- 1005 or PPI-1009, respectively were effectively converted to PlsEtn species in cells with impaired plasmalogen biosynthesis capacity (N-ReI, Figures 2, 3A) and in cells with unimpaired plasmalogen biosynthesis capacity (CHO, Figure 4A). These results are in direct contrast to the prior art regarding other plasmalogen precursors. 1 -alkyl, 2-hydroxy glycerols (chimyl, batyl, salachyl alcohols) has been shown to increase PlsEtn levels in PlsEtn deficient systems to control levels but not to above control levels in either PlsEtn deficient or PlsEtn sufficient systems (Figure 4B). In addition the bioconversion of the 1-alkyl, 2-acyl glycerols described in this invention did not result in increased levels of either chimyl alcohol or 1- alkenyl, 2-acyl glycerols (Figure 3B) indicating that neither chimyl alcohol nor 1 -alkenyl, 2- acyl glycerols are intermediates in the biotransformation pathway of the described molecules to PlsEtn.
The compound PPI-005 is described in applicant's co-pending application PCT/CA2007/001472, and is shown below:
Figure imgf000027_0001
(4Z,7Z,10Z,13Z,16Z,19Z)-1-(hexadecyloxy)-3-hydroxypropan-2-yl docosa-4,7,10, 13,16, 19-hexaenoate
5a
Treatment of cells with 1-alkyl, 2-acyl glycerols with 16:0 at sn-1, DHA at sn-2 and either OH or acetyl -L-carnitine at sn-3 resulted in the structure-specific enrichment of PlsEtn with DHA at sn-2 (Figure 6). This is the first description of the structure-specific enrichment of PlsEtn.
PPI- 1009 is a plasmalogen precursor with improved pharmaceutical properties. This molecule exists at room temperatures as a salt and represents the first non-oil based plasmalogen precursor ever reported.
Biological systems with a pre-existing deficiency in plasmalogen synthesis and subsequent low plasmalogen levels (N-ReI vs. CHO) (Figure 1) have elevated membrane cholesterol levels (Figure 5). Elevation of DHA-PlsEtn to 80% of control values by PPI- 1005 (Figure 2) resulted in a significant reduction in membrane cholesterol (Figure 5).
The cholesterol lowering effect of elevated PlsEtn levels was discovered to be dependent upon the sn-2 substituent (Figures 7 and 8). Only polyunsaturated fatty acids (DHA, 18:3) were observed to have cholesterol lowering activity in HEK293 cells whereas saturated, mono and diunsaturated fatty acids had no effect. Only the restoration of DHA-PlsEtn levels resulted in a robust attenuation of the elevated membrane cholesterol levels observed in N- ReI cells as a result of decreased plasmalogen levels (Figure 7). These results indicate that poly-unsaturated fatty acid containing PlsEtn are selectively involved in membrane cholesterol homeostasis. PPI- 1009 was also demonstrated to concentration-dependently decrease membrane cholesterol levels in NReI (Figure 7) and HEK293 cells (Figure 9). These results indicate that the membrane lowering effect of elevated PlsEtn levels requires the administration of plasmalogen precursor capable of selectively elevating PlsEtn levels with specific sn-2 substitutions.
The treatment of HEK293 cells with either PPI- 1005 or PPI- 1009 resulted in decreased levels of both AB-40 and AB-42 in both normal cells and cholesterol loaded cells (Figure 10). These results further exemplify the functional utility of the plasmalogen precursors by their ability to positively modulate membrane protein function. In this regard, decreased membrane cholesterol levels are known to negatively modulate amyloid peptide production15. In addition to lowering membrane cholesterol in HEK293 cells, PPI-1005 and PPI- 1009 were also observed to decrease the secretion of amyloid peptides (Figure 10).
A structure-specific and concentration-dependent incorporation of PPI-1014 in N-ReI ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) was also observed after 72 hours using 5, 10 and 20 μM concentrations of PPI-1014 (Figure 17).
EXAMPLE 3: Preparation of PPI-1011
Figure imgf000028_0001
PPI-1011
MW = 815.32 MF = C49H82O5S2
Synthetic scheme:
Figure imgf000029_0001
Synthetic scheme for PPI-1011
Figure imgf000029_0002
Reaction step:
Figure imgf000029_0003
1 Brief procedure: A solution of compound 1 (2.0 Kg, 15.15 mol) in 10% NaOH solution (10.0 L) was stirred at 8O0C for Ih, TBAB (992.Og, 3.03 mol) added and stirred for 15 min. Cetyl bromide (5.5 kg, 18.18 mol) was added slowly and the reaction mixture was stirred at 8O0C for 2Oh. {The reaction progress was monitored by diluting small aliquots with water, extracting with ethyl acetate and spotting over an analytical silica gel TLC plate (30 % Ethyl acetate in pet-ether) and visualizing respective spots using Mo stain and KMnO 4 solution). The following are the RfS of the components of the mixture: compound 1 (0.1), compound 2 (0.7).
Work up and purification: The reaction mixture was cooled to RT, extracted with CH2Cl2 (3 x 3.0 L). The combined CH2Cl2 layer was washed with NaHCO3 solution (1.0 L), water (2 x 2.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated to afford crude compound 2 (2.9 Kg, crude) as pale yellow liquid, which was used in next step.
Reaction step:
Figure imgf000030_0001
Brief procedure: A solution of compound 2 (2.9 Kg, 81.23 mol) in 20% aq HCl (14.5 L) was stirred at 850C for 16h. (The reaction progress was monitored by diluting small aliquots with water, extracting with ethyl acetate and spotting over an analytical silica gel TLC plate (40% ethyl acetate in pet ether) and visualizing spots using Mo stain). The following are the Rjs of the components of the mixture: compound 2 (0.8), compound 3 (0.2).
Work up and purification: The reaction mixture was cooled to RT, extracted with CH2Cl2 (3 x 4.0 L). The combined organic layer was washed with NaHCO3 solution (1.0 L), water (2 x 2.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated to afford crude compound, which was triturated with 5% ethyl acetate in pet-ether (2 x 1.0 L) and dried to afford compound 3 (2.0 Kg, 42% from 2-steps) obtained as off white solid.
Reaction step:
Figure imgf000031_0001
Brief procedure: To a cooled solution of compound 3 (1.0 Kg, 3.16 mol) in DMF (640.0 niL) and CH2Cl2 (400.0 niL) at O0C, added DMAP (38.6 g, 0.32 mol) followed by triethylamine (735.0 g, 7.27 mol). After addition the reaction mixture was stirred at O0C for 30 min and added TBSCl (572.0 g, 3.79mol) in equal portions (3 portions) for Ih and the reaction mixture was stirred for 2Oh at RT. (The reaction progress was monitored by quenching small aliquots with water, extracting with CH2CI2 and spotting over an analytical silica gel TLC plate (20% Ethyl acetate in pet ether) and visualizing spots using Mo stain and KMnO4). The following are the RfS of the components of the mixture: compound 3 (0.15), compound 4(0.7).
Work up and purification: The reaction mixture was diluted with CH2Cl2 (2.0 L), washed with water (3 x 3.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated. The obtained crude compound was purified by column chromatography (silica gel 100-200 mesh) using 5 % ethyl acetate in pet ether as eluent to afford compound 4 (850 g, 90%) obtained as pale yellow oil.
Reaction step:
Figure imgf000031_0002
Brief procedure: To a cooled solution of compound 5 (160.0 g, 0.487 mol), DMF (1.0 mL) in CH2Cl2 (500.OmL) at O0C, Oxalyl chloride (105.0 g, 0.828 mol) was added slowly for 30 min. After addition the reaction mixture was stirred at 260C for 4h. (The reaction progress was monitored by quenching small aliquots with MeOH and spotting over an analytical silica gel TLC plate (10% Ethyl acetate in pet ether) and visualizing spots using KMnO4 solution). The following are the RfS of the components of the mixture: compound 5 (0.3), compound 6 (0.8). Work up and purification: The reaction mixture was concentrated under N2 atmosphere to afford crude compound 6 (175 g, crude).
Reaction step:
Figure imgf000032_0001
Brief procedure: To a cooled solution of compound 4 (150.0 g, 0.348 mol) in Toluene (1.25 L) at O0C, pyridine (110.0 g, 1.39 mol) was added followed by DMAP (122.2g, 0.348 mol) and stirred for 10 min. Added a solution of crude compound 6 (175.O g, 0.504 mol) in Toluene (250.0 mL) for 15 min. After addition the reaction mixture was stirred at RT for 2Oh. (The reaction progress was monitored by quenching small aliquots with water, extracting with EtOAc and spotting over an analytical silica gel TLC plate (5% Ethyl acetate in pet ether) and visualizing spots using KMnO 4 solution). The following are the RfS of the components of the mixture: compound 4 (0.2), compound 7 (0.5).
Work up and purification: The reaction mixture was diluted with ethyl acetate (3.0 L), washed with water (1.0 L), 0.05 N HCl (500.0 mL), water (2 x 1.0 L), brine solution (500.0 mL) dried over anhydrous Na2SO4 and concentrated to afford crude compound 7, which was purified by column chromatography (silica gel 100-200 mesh) using 2 % ethyl acetate in pet ether as eluent to afford compound 7 (162 g, 62.7%) obtained as pale yellow oil.
Reaction step:
Figure imgf000032_0002
Brief procedure: To a cooled solution of compound 7 (160.0 g, 216.21 mmol) in THF (10.OmL) and acetic acid (52.0 g) at O0C, TBAF (226.0 g, 864.86 mmol) was added in equal portions for 30min. After addition the reaction mixture was stirred at RT for 6h. (The reaction progress was monitored by spotting over an analytical silica gel TLC plate (20% Ethyl acetate in pet ether) and visualizing spots using Mo stain and KMnO 4 solution). The following are the RfS of the components of the mixture: compound 7 (0.9), compound PPI- 1005 (0.4).
Work up and purification: The reaction mixture was diluted with ethyl acetate (3.0 L), washed with water (2 x 2.0 L), brine (500.0 mL), dried over anhydrous Na2SO4 and concentrated to afford crude compound, which was purified by column chromatography (silica gel 100-200 mesh) using 7 % ethyl acetate in pet ether as eluent to afford compound PPI-1005 (72 g, 53%) obtained as pale yellow oil.
Reaction step:
Figure imgf000033_0001
Brief procedure: To a cooled solution of α-Lipoic acid 1 (12.0 g, 58.25 mmol) in THF (500.0 mL) at O0C, triethylamine (8.1 mL, 58.25 mmol) was added slowly for 10 min, followed by 2,4,6-Trichlorobenzoyl chloride (14.2 g, 58.25 mmol). After addition the reaction mixture was allowed to RT and stirred for 18h. (The reaction progress was monitored by spotting on an analytical silica gel TLC plate (20% EtOAc in pet-ether), and visualizing spots using 254 nm UV light and Hanessian 's stain). The following are the RfS of the components of the mixture: compound 1 (0.2), intermediate (0.6). The reaction mixture was filtered off, the solid was washed with THF (25.0 rnL), the combined filtrate was concentrated using reduced pressure under ^atmosphere to obtain the crude anhydride, which was dissolved in benzene (500.0 mL, cooled to O0C and added DMAP (7.1 g, 58.25 mmol), stirred for 10 min. To the reaction mixture added a solution of PPI-1005 (40. Ig, 64.07 mmol) in benzene (100.0 mL) slowly at O0C. After addition the reaction mixture was allowed to RT and stirred for 24h.(The reaction progress was monitored by quenching small aliquots with H2O, extracting with ethyl acetate and spotting on an analytical silica gel TLC plate (15% THF in pet-ether), and visualizing spots using 254 nm UV light and Hanessian 's stain). The following are the RfS of the components of the mixture: PPI-1005 (0.3), PPI-1011 (0.5).
Work up and purification: The reaction mixture was diluted with ethyl acetate (200OmL), washed with saturated NaHCO3 solution (1 x 400 mL), 0.05N HCl (1 x 400 mL), water (1 x 400 mL), brine (1 x 400 mL) and dried over anhydrous Na2SO4 and concentrated to obtain the crude compound, which was purified by column chromatography (neutral silica gel 100-200 mesh) using 2.5 to 5% THF in pet ether as eluent.
The title compound PPI-1011 (28.0 g, 54%) was obtained as pale brown oil.
EXAMPLE 4: Alternate method for preparation of PPI-1009
Figure imgf000034_0001
MW = 813.25 MF = C50H86NO7 Synthetic scheme:
Figure imgf000035_0001
850C, 16h 20%aq HCI 42% (2-steps)
Figure imgf000035_0002
PPM 009
Reaction step:
Figure imgf000035_0003
Procedure: A solution of compound 1 (2.0 Kg, 15.15 mol, Alfa Aesar) in 10% NaOH solution (10.0 L) was stirred at 8O0C for Ih, added TBAB (992.Og, 3.03 mol, Rajdhani scientific) and stirred for 15 min. Added cetyl bromide (5.5 kg, 18.18 mol, Alfa Aesar) slowly and the reaction mixture was stirred at 8O0C for 2Oh. {The reaction progress was monitored by diluting small aliquots with water, extracting with ethyl acetate and spotting over an analytical silica gel TLC plate (30 % Ethyl acetate in pet-ether) and visualizing respective spots using Mo stain and KMnO U solution). The following are the RfS of the components of the mixture: compound 1 (0.1), compound 2 (0.7). The reaction mixture was cooled to RT, extracted with CH2Cl2 (3 x 3.0 L). The combined CH2Cl2 layer was washed with NaHCO3 solution (1.0 L), water (2 x 2.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated to afford crude compound 2 (2.9 Kg, crude) as pale yellow liquid, which was used in next step.
Reaction step:
Figure imgf000036_0001
Procedure: A solution of compound 2 (2.9 Kg, 81.23 mol) in 20% aq HCl (14.5 L) was stirred at 850C for 16h. (The reaction progress was monitored by diluting small aliquots with water, extracting with ethyl acetate and spotting over an analytical silica gel TLC plate (40% ethyl acetate in pet ether) and visualizing spots using Mo stain). The following are the RfS of the components of the mixture: compound 2 (0.8), compound 3 (0.2). The reaction mixture was cooled to RT, extracted with CH2Cl2 (3 x 4.0 L). The combined organic layer was washed with NaHCO3 solution (1.0 L), water (2 x 2.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated to afford crude compound, which was triturated with 5% ethyl acetate in pet-ether (2 x 1.0 L) and dried to afford compound 3 (2.0 Kg, 42% from 2- steps) obtained as off white solid.
Reaction step:
Figure imgf000037_0001
Procedure: To a cooled solution of compound 3 (1.0 Kg, 3.16 mol) in DMF (640.0 mL) and CH2Cl2 (400.0 mL) at O0C, added DMAP (38.6 g, 0.32 mol) followed by triethylamine (735.0 g, 7.27 mol, Rankem). After addition the reaction mixture was stirred at O0C for 30 min and added TBSCl (572.0 g, 3.79mol, Fluoro chem 3.0 kg) in equal portions (3 portions) for Ih and the reaction mixture was stirred for 2Oh at RT. (The reaction progress was monitored by quenching small aliquots with water, extracting with CH2CI2 and spotting over an analytical silica gel TLC plate (20% Ethyl acetate in pet ether) and visualizing spots using Mo stain and KMnθ4). The following are the RfS of the components of the mixture: compound 3 (0.15), compound 4(0.7). The reaction mixture was diluted with CH2Cl2 (2.0 L), washed with water (3 x 3.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated. The obtained crude compound was purified by column chromatography (silica gel 100-200 mesh) using 5 % ethyl acetate in pet ether as eluent to afford compound 4 (850 g, 90%) obtained as pale yellow oil.
Reaction step:
Figure imgf000037_0002
Procedure: To a cooled solution of compound 4 (734 g, 1.706 mol) in DMF (2.5 L) at O0C, added 60% NaH (204.0 g, 5.12 mol) in portions for 30min. After addition the reaction mixture was stirred at O0C for further 30 min and added benzyl bromide (438.0 g, 2.56 mol, S. D fine chemicals) drop wise for Ih. The reaction mixture allowed to RT was stirred for 2Oh. (The reaction progress was monitored by quenching small aliquots with water, extracting with EtOAc and spotting over an analytical silica gel TLC plate (5% Ethyl acetate in pet ether) and visualizing spots using Mo stain and KMnO4). The following are the RfS of the components of the mixture: compound 4 (0.2), compound 5(0.5). The reaction mixture was quenched with methanol (250 mL), cold water (1500 mL) and extracted using ethyl acetate (2 x 2.0 L). The combined ethyl acetate layer was washed with water (3 x 1.0 L), brine solution (1.0 L), dried over anhydrous Na2SO4 and concentrated. The obtained crude compound 5 (887 g) was used in the next step without further purification.
Reaction step:
Figure imgf000038_0001
Procedure: To a cold solution of crude compound 5 (887.0 g, 1.702 mol) in THF (2.0 L) at O0C, a solution of TBAF (1.3 Kg, 5.107 mol, Chemrich fine chemicals) in THF (1.0 L) was added slowly for Ih. After addition the reaction mixture was stirred at RT for 16h. (The reaction progress was monitored by quenching small aliquots with water, extracting with EtOAc spotting over an analytical silica gel TLC plate (30% Ethyl acetate in pet ether) and visualizing spots using Mo stain and KMnO 4 solution). The following are the RfS of the components of the mixture: compound 5 (0.9), compound 6 (0.3). The reaction mixture was diluted with ethyl acetate (2.5 L), washed with water (2 x 1.0 L), brine (1.0 L), dried over anhydrous Na2SO4 and concentrated to afford crude compound, which was purified by column chromatography (silica gel 100-200 mesh) using 7 % ethyl acetate in pet ether as eluent to afford compound 6 (330 g, 48% from 2 steps) obtained as pale yellow oil.
Reaction step:
Figure imgf000038_0002
Procedure: To a cold solution ofN-Acetyl carnitene 8 (239.0 g, 1.177 mol, Molecula life Sciences) in CH2Cl2 (500.0 mL) and DMF (5.0 mL) at O0C, added oxalyl chloride (179.4 g, 1.412 mol) slowly for 30 min and stirred at RT for 4h. The solvent from the reaction mixture was removed by distillation under reduced pressure and traces of oxalyl chloride by co- distilling with CH2Cl2. The obtained crude compound 9 (25Og) was dissolved in CH2Cl2 (500.0 mL) and added slowly to a cold solution of compound 6 (334.0 g, 0.823 mol) in CH2Cl2 (500.0 mL) at O0C with bubbling N2 gas. After addition the reaction mixture was stirred for 2Oh with continuous bubbling of N2 at RT. (The reaction progress was monitored by quenching small aliquots with water, extracting with CH2CI2 and spotting over an analytical silica gel TLC plate (25% MeOH in chloroform) and visualizing spots using Mo stain and KMnO 4). The following are the RfS of the components of the mixture: compound 6 (0.8) and compound 10 (0.3). The reaction mixture was diluted with CH2Cl2 (2.0 L), washed with brine solution (250 mL), dried over anhydrous Na2Sθ4 and concentrated to obtain crude compound which was purified by column chromatography (silica gel 100-200 mesh) using 5 % MeOH in chloroform as eluent to afford compound 10 (153.0 g, 31.5%) obtained as pale yellow oil.
Reaction step:
Figure imgf000039_0001
Brief procedure: To a suspension of 10% Pd/C (40.0 g, 25% w/w, AlfaAesar) in ethanol (1.2 L), compound 10 (150 g, 0.298 mol) was added and hydrogenated (H2, 40 psi pressure) at RT for 2Oh. (The reaction progress was monitored by spotting over an analytical silica gel TLC plate (25% MeOH in chloroform) and visualizing spots using Mo stain and Ninhydrin solution). The following are the RfS of the components of the mixture: compound 10 (0.4), compound 11(0.2). The reaction mixture was filtered off through celite bed, washed the cake with ethanol (2 x 200 mL), the combined filtrate was concentrated to obtain crude compound, was purified by column chromatography (silica gel 100-200 mesh) using 10 % Methanol in chloroform as eluent to afford compound 11 (75 g, 60%) obtained as pale yellow oil.
Reaction step:
Figure imgf000040_0001
Brief procedure: To a cooled solution of compound 5 (48.0 g, 0.146 mol, Nu-Chek-Prep Inc), DMF (1.0 niL) in CH2Cl2 (300.OmL) at O0C, Oxalyl chloride (22.3 g, 0.175 mol, Molecula Lifesciences) was added slowly for 30 min. After addition the reaction mixture was stirred at 260C for 4h. (The reaction progress was monitored by quenching small aliquots with MeOH and spotting over an analytical silica gel TLC plate (10% Ethyl acetate in pet ether) and visualizing spots using KMnO 4 solution). The following are the RfS of the components of the mixture: compound 12 (0.3), compound 13 (0.8). The reaction mixture was concentrated under N2 atmosphere to afford crude compound 6 (57 g, crude).
Reaction step:
13 THF 20h
Figure imgf000040_0003
Figure imgf000040_0002
Brief procedure: To a cooled solution of compound 11 (50.0 g, 0.102 mol) in THF (1.0 L) at O0C, pyridine (32.3 g, 0.409 mol) was added followed by DMAP (12.5g, 0.102 mol) and stirred for 10 min. Added a solution of crude compound 13 (57.0 g, 0.163 mol) in Toluene (1.0 mL) for 15 min. After addition the reaction mixture was stirred at RT for 2Oh. (The reaction progress was monitored by quenching small aliquots with water, extracting with EtOAc and spotting over an analytical silica gel TLC plate (20% Methanol in chloroform) and visualizing spots using Mo stain and Ninhydrin solution). The following are the RfS of the components of the mixture: compound 11 (0.2) and PPI-1009 (0.5). The reaction mixture was diluted with ethyl acetate (2.0 L), washed with 0.5N HCl (250 mL), brine solution (250.0 mL) dried over anhydrous Na2SO4 and concentrated to afford crude compound, which was purified by column chromatography (silica gel 100-200 mesh) using 20 % Methanol in chloroform as eluent to afford compound PPI-1009 (27 g, 33.3%) obtained as pale yellow oil. EXAMPLE 5; Preparation of PPI-1014
Target molecule
Figure imgf000041_0001
MW = 772.19 MF = C46H77NO6S
Synthetic scheme:
Figure imgf000041_0002
Reaction step:
Figure imgf000042_0001
Reaction time: 17h Reaction temperature: O0C to 26 0C Brief procedure: To a cooled solution of PPI-1005 (12.0 g, 19.16 mmol) in THF (600 niL), added Triphenyl phosphene (7.5 g, 28.75 mmol) and stirred at O0C for 10 min, followed by slow addition of DIEAD (5.8g, 28.75 mmol). After stirring at O0C for 30 min the reaction mixture was added N- Acetyl cystine (4.6 g, 28.75 mmol) and allowed to stir at RT for 16h. (The reaction progress was monitored by extracting with ethyl acetate and spotting on an analytical silica gel TLC plate (30% Ethyl acetate in pet-ether), and visualizing spots using Mo stain). The following are the RfS of the components of the mixture: PPI-1005 (0.8), PPI- 1014 (0.4).
Work up and purification: The reaction mixture was diluted with water (75 mL) and extracted using ethyl acetate (3 x200mL). The combined ethyl acetate layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated to afford the crude compound, which was purified by column chromatography (100-200 mesh silica gel) using 0 to 13% ethyl acetate in pet ether as eluent.
The title compound PPI-1014 (3.2 g, 22%) was obtained as pale yellow oil exhibited the following properties. 1H NMR (300 MHz, CDCl3): δ 6.35 (bs, IH), 5.39-5.22 (m, 13H), 4.92-4.88 (m, IH), 4.55-4.22 (m, 3H), 3.55-3.41 (m, 5H), 3.02-2.97 (m, 2H), 2.85-2.77 (m, 10H), 2.40 (s, 5H), 2.112.04 (m, 5H), 1.57-1.52 (m, 2H), 1.36-1.25 (m, 30H), 0.97 (t, J= 7.66Hz; 3H), 0.88 (t, J= 6.63Hz; 3H).Mass (M+H): 772.3, HPLC purity~93.68%.
EXAMPLE 6: Animal Studies
Male New Zealand rabbits (1.8-2.5 kg) were orally dosed with PPI-101 1, neat in hard gelatin capsules (size 3). For time course studies, rabbits were dosed with 200 mg/kg of PPI-1011 and animals sacrificed via euthenol overdose at 1, 3, 6, 12, 18, 24 and 48 hr. Blood was collected by cardiac puncture and plasma frozen at -7O0C for later analysis. Kidney and liver also were harvested and stored at -7O0C for later analysis. These studies were conducted as 2 experiments with overlapping groups at 12 hrs (Exp. 1 : 1, 3, 6, and 12 hrs; Exp. 2: 12, 18, 24 and 48 hrs). Controls were harvested at each timepoint. Plasmalogens and lipids were extracted and analyzed by LC-MS/MS as previously reported (Goodenowe et al., 2007).
As seen in Figure 11, using an oral dose of 200 mg/kg the plasmalogen precursor PPI-1011 was incorporated into circulating plasmalogens. Deacylation at sn-2, releasing docosahexaenoic acid (DHA), also was observed. The greatest incorporation was into the 16:0/22:6, 18:0/22:6 and 18:1/22:6 ethanolamine plasmalogens and phosphatidylethanolamines. No change in the reference phosphatidylethanolamine 16:0/18:0 was observed.
Further examination of the timecourse (Figure 12) of incorporation in plasma revealed that maximum incorporation was at 12 hours and that this level of incorporation was maintained over the remaining observation period (48 hr). This was the case for both the phosphatidylethanolamines and the ethanolamine plasmalogens. In contrast, circulating DHA levels peaked at 6 hours and fell to a lesser steady-state by 18 hours.
Studies of dose-dependent incorporation (Figure 13) of PPI- 1011 into plasma plasmalogens and phosphatidylethanolamines demonstrated that a new steady-state level in these circulating phospholipids was attained in a dose-dependent manner from 10 to 200 mg/kg. However, further increases in dose did not increase the steady-state levels of plasmalogens and phosphatidylethanolamines above that obtained with 200 mg/kg. In contrast, the highest steady-state levels of circulating DHA were obtained at 500 mg/kg and did not further increase at a dose of 1000 mg/kg.
Augmentation of tissue plasmalogens and DHA was also observed in kidney (Figures 4 and 5) and liver (Figures 6) tissues.
These results indicate that PPI-1011 is orally bioavailable in the rabbit and is converted to DHA-containing ethanolamine plasmalogens and phosphatidylethanolamines via deacylation/re-acylation reactions. In addition, the results suggest that endogenous metabolic systems may limit the maximal increase that that can be pharmacologically augmented. EXAMPLE 7: Modulating membrane protein abundance in vitro with plasmalogen precursors
The following studies demonstrate the effectiveness of a plasmalogen precursor (l-alkyl-2 acyl glycerol) in altering the abundance of membrane-resident proteins. The cellular effects of the compound are demonstrated in wild-type cells, as well as in conditions of artificially elevated membrane cholesterol.
In wild-type cells, an elevation of amyloid precursor protein (APP) modulating enzyme ADAMlO and cholesterol esterification protein SOATl was observed with an increase in plasmalogen precursor concentration. Similar effects were observed in a cholesterol-loaded model. Additionally, a different APP processing enzyme, BACEl, showed a decrease in abundance only in cholesterol loaded cells. Without wishing to be bound by theory, this evidence supports a method of reducing the amyloid load in the context of Alzheimer's disease and simultaneously re-equilibrating the membrane cholesterol content of the system, thereby offering potential benefits in the treatment of diseases like atherosclerosis and hypercholesterolemia, in addition to Alzheimer's disease.
APP is predominantly processed by a canonical pathway comprised of sequential cleavage by γ-secretases (encoded by presenilinl/2 genes) and α-secretase (encoded by ADAMlO). This non-pathological processing of APP results in the formation of a neutotrophic peptide (sAPPα) which exhibits protection against glutamate toxicity and hypoglycemia (Araki et al., 1991; Mattson et al., 1993; Postina et al., 2004; Fahrenholz, 2007). An alternate APP processing pathway manifests itself in Alzheimer's disease, wherein APP is cleaved by γ- and β-secretases in cholesterol-rich lipid rafts. This "non-canonical" pathway results in the formation of Aβ peptides 38-43 amino acids long which tend to aggregate into plaques in the extracellular matrix, a hallmark of AD (Selkoe, 2002; Walsh et al., 2002; Selkoe, 2003; Meyer-Luehmann et al., 2008). While early-onset familial AD is explained by genetic lesions in APP or APP processing enzymes (PSEN1/2, BACE, ADAM), the underlying cause of late- onset sporadic AD (switch from non-pathogenic to pathogenic APP processing) remains unclear.
The importance of cholesterol homeostasis in the etiology of AD has been investigated in humans (Corder et al., 1993; Saunders et al., 1993; Blacker et al., 1997; Hofman et al., 1997) and in animal models (Joyce et al., 2002; Singaraja et al., 2002; Van Eck et al., 2006; Wahrle et al., 2008). Altering the cholesterol content of the plasma membrane has been shown to affect the function of membrane resident proteins (Scanlon et al., 2001; Lange et al., 2004). Elevated brain cholesterol was shown in subjects with AD (Mori et al., 2001), while rabbits fed on a cholesterol-rich diet have been shown to develop plaques in the brain (Ghribi et al., 2006). In vitro data showed that plasmalogen deficient cells possess elevated free-cholesterol in the membrane, while in humans, serum-plasmalogen deficiency has been shown to correlate with a decline in cognition status (Goodenowe et al., 2007). Based on these observations, we investigated the interplay between cholesterol and plasmalogens, and identify how the balance between the two affects the pathological manifestations of AD, measured in terms of secreted Aβ.
Proposed mode of action: A shift in APP processing via membrane lipid modulation
Human embryonic kidney (HEK293) cells express APP and the membrane-bound machinery required to process APP, making it a good model to study APP processing. The present in vitro investigation corroborated previous studies in that modulating membrane fluidity via cholesterol loading and/or plasmalogen precursor supplementation altered the extracellular Aβ42 content. Cholesterol loading of HEK293 cells increases the amount of free cholesterol by 17% (compared with Control) in the cells following a 48 hour incubation period. This elevation is accompanied with a parallel and significant increase (p<0.05) in the Aβ42 content in the conditioned medium compared with control. The 65% increase in amyloid is primarily due to 22 % increase in β-secretase concentration (Figure 18A, lane 2); the basal APP levels remain unchanged with cholesterol loading. Treatment of the cholesterol loaded HEK293 system with plasmalogen precursor PPI- 1005 significantly reduced the free cholesterol content of the cell membrane (p<0.05). The Aβ42 content in the conditioned medium dropped 70% below cholesterol-loaded levels at the 20μM concentration (p=0.0001), while the sAPPα content in the conditioned medium was elevated. The effects on APP processing do not appear to be due to a change in APP expression, rather it appears to be due to a shift in the APP processing pathway by virtue of changes in the abundance of APP processing enzymes. While β-secretase was restored to normal levels at 20μM concentration of PPI-1005, a 73% increase in sAPPα species was detected in the conditioned medium. This elevation was explained by 63% increase in ADAMlO (Figure 18A, lane 3), the enzyme responsible for sAPPα formation.
The change in cholesterol profile of the cells following plasmalogen supplementation can be explained by the observation that SOATl, the enzyme responsible for esterification of free cholesterol is approximately 25% upregulated (compared with the cholesterol loaded condition) with increasing plasmalogen concentration (Figure 18A, lane 5).
In a separate study, the effects of PP I- 1005 were investigated in wild-type HEK293 cells, not loaded with cholesterol. Figure 18B shows a concentration-dependent increase in abundance of ADAMlO (35%) and SOATl (50%); No change in BACEl or APP abundance was observed. Although when HEK293 cells were depleted of cholesterol by HMGCoA reductase inhibition by pravastatin, ADAMlO and SOATl protein levels remained constant (Figure 18C). While plasmalogen and pravastatin treatments both significantly reduce the fraction of free cholesterol in the cells, it is the plasmalogen treatment alone that alters ADAMlO and SOAT levels in the cell. This suggests that the effects on ADAMlO and SOATl abundance is an effect of membrane plasmalogen content rather than membrane cholesterol content.
Accordingly, the abundance of membrane-resident proteins can be altered in vitro by modulating the cellular plasmalogen content, which is achieved by treating cells with plasmalogen precursors as described herein.
Materials and Methods
Cholesterol loading
HEK 293 cells, cultured in DMEM, 10% FBS at 37°C, 5% CO2, were seeded the day before the treatment. The following day, cells membranes were loaded with exogenous cholesterol at a concentration of lOμg/ml media using methyl-β-cyclodextrin as the carrier to deliver cholesterol as described (Rong et al., 2003).
Cholesterol Assay
Cells were treated with the plasmalogen precursor PPI- 1005 or with ethanol as the control. Cells were harvested after 48 hours using Versene: TryPLe express cocktail, washed with PBS. Lipids were extracted with chloroform containing l%Triton X-IOO. The organic fraction was recovered and dried under a stream of nitrogen. The dried lipids were resuspended in cholesterol reaction buffer (Biovision, Mountain View, CA), and the total, free and esterified fractions of cholesterol were quantified using the cholesterol quantification kit (Biovision, Mountain View, CA) as per the manufacturer's recommendations. Cholesterol was initially calculated as μg/million cells, and reported as a percentage of control conditions for each experiment.
Amyloid Assay
HEK293 cells were loaded with exogenous cholesterol as described, and treated with a PPI 1005 or with ethanol as a control. Conditioned media from the treated cells was collected at the end of a 48 hour incubation period. For assaying Aβi_42 content, the conditioned media was enriched using Amicon ultracentrifugal filter devices (Millipore, Billerica, MA) prior to loading into the microplate. ELISA was carried out as per the manufacturer's recommendations (Covance Labs, Princeton, NJ). The reactions were quenched 25 minutes after addition of the substrate, and the absorbance was read at 495nm. The experiment was carried out in triplicate. Values were calculated as pg/ml of conditioned media, and were normalized to the amount of Aβ detected in the conditioned media from untreated, cholesterol loaded control HEK293 cells.
Immunoblotting and Immunoprecipitation
HEK293 cells were treated as described in the amyloid assay. The cell pellet was washed in PBS and lysed in a RIPA buffer containing a protease inhibitor cocktail (Sigma, St. Louis, MI). Protein in the cell lysate was quantified using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). The following antibodies were used for western analyses: APP (Calbiochem, Darmstadt, Germany), BACEl and ADAMlO (Millipore, Temecula, CA), sAPPα (IBL, Gunma, Japan), SOATl (Santa Cruz Biotechnology Inc., CA), and β-actin (Sigma, St. Louis, MI). Immunoprecipitation was carried out to estimate sAPPα in the conditioned medium. Briefly, antibody to sAPPα was added to conditioned media and incubated for 16 hours at 40C. IP was carried out by incubating with protein A/G agarose beads for 6 hours at 40C. Beads were washed with PBS and the eluted proteins were detected by immunoblotting with anti-sAPPα antibody. Band intensities were quantified using Image Processing and Analysis in Java (ImageJ) software (National Institutes of Health, Bethesda, MD) Statistical analysis
Statistical Analysis of the data was performed using Microsoft™ Office Excel 2007 and JMP version 8. Multiple comparison Dunnett's tests were applied to analyze the differences between the treatments and the control.
It will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
The following references, as well as those references provided above, are hereby incorporated by reference.
References
1. Calderini G, Bonetti AC, Battistella A, Crews FT, Toffano G (1983) Biochemical changes of rat brain membranes with aging. Neurochem Res. 8:483-92.
2. Hashimoto M, Hossain S, Masumura S (1999) Effect of aging on plasma membrane fluidity of rat aortic endothelial cells. Exp Gerontol. 34:687-98.
3. Kessler AR, Kessler B, Yehuda S (1985) Changes in the cholesterol level, cholesterol-to- phospholipid mole ratio, and membrane lipid microviscosity in rat brain induced by age and a plant oil mixture. Biochem Pharmacol. 34: 1120-1.
4. Lewin MB, Timiras PS (1984) Lipid changes with aging in cardiac mitochondrial membranes. Mech Ageing Dev. 24:343-51.
5. Modi HR, Katyare SS, Patel MA (2008) Ageing-induced alterations in lipid/phospholipid profiles of rat brain and liver mitochondria: implications for mitochondrial energy-linked functions. J Membr Biol. 221 :51-60.
6. Wu CC, Su MJ, Chi JF, Wu MH, Lee YT (1997) Comparison of aging and hypercholesterolemic effects on the sodium inward currents in cardiac myocytes. Life Sci. 61 : 1539-51. 7. Guo J, Chi S, Xu H, Jin G, Qi Z (2008) Effects of cholesterol levels on the excitability of rat hippocampal neurons. MoI Membr Biol. 25:216-23.
8. Santiago J, Guzman GR, Rojas LV, Marti R, Asmar-Rovira GA, Santana LF, McNamee M, Lasalde-Dominicci JA (2001) Probing the effects of membrane cholesterol in the Torpedo californica acetylcholine receptor and the novel lipid-exposed mutation alpha C418W in Xenopus oocytes. J Biol Chem. 276:46523-32.
9. Hashimoto M, Hossain S, Tanabe Y, Shido O (2005) Effects of aging on the relation of adenyl purine release with plasma membrane fluidity of arterial endothelial cells. Prostoglandins Leukot. Essent. Fatty Acids. 73 :475-83.
10. Xiu J, Nordberg A, Qi X, Guan ZZ (2006) Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem Int. 49:459-65.
1 1. Miersch S, Espey MG, Chaube R, Akarca A, Tweten R, Ananvoranich S, Mutus B (2008) Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling. J Biol Chem. 283: 18513-21. 12. Cultler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A. 101 :2070-5. 13. Corrigan FM, Horrobin DF, Skinner ER, Besson JA, Cooper MB ( 1998) Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol. 30: 197-207.
14. Distl R, Meske V, Ohm TG (2001) Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol. 101 :547-54.
15. Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C (2008) Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. J Biol Chem. 283:11302-11.
16. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.
Proc Natl Acad Sci U S A. 95:6460-4.
17. Beel AJ, Mobley CK, Kim HJ, Tian F, Hadziselimovic A, Jap B, Prestegard JH, Sanders CR (2008) Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry. 47:9428-46.
18. Sigle JP, Zander J, Ehret A, Honegger J, Jackisch R, Feuerstein TJ (2003) High potassium-induced activation of choline-acetyltransferase in human neocortex: implications and species differences. Brain Res Bull. 60:255-62.
19. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med.
5:20.
20. Li CM, Clark ME, Rudolf M, Curcio CA (2007) Distribution and composition of esterified and unesterified cholesterol in extra-macular drusen. Exp Eye Res. 85:192-201.
21. Hager MH, Solomon KR, Freeman MR (2006) The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. ;9:379-85.
22. Campbell AM, Chan SH (2008) Mitochondrial membrane cholesterol, the voltage dependent anion channel (VDAC), and the Warburg effect. J Bioenerg Biomembr. 23. Vejux A, Malvitte L, Lizard G (2008) Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Braz J Med Biol Res. 41 :545-56.
24. Streit WJ, Sparks DL (1997) Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J MoI Med. 75:130-8. 25. Diestel A, Aktas O, Hackel D, Hake I, Meier S, Raine CS, Nitsch R, Zipp F, Ullrich O (2003) Activation of microglial ρoly(ADP-ribose)-polymerase-l by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med. 198:1729-40.
26. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, Bhat NR (2008) High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 106:475-85.
27. Shin J, Thompson DH (2003) Direct synthesis of plasmenylcholine from allyl-substituted glycerols. J Org Chem. 68:6760-6. 28. Gupta CM, Radhakrishnan R, Khorana HG (1977) Glycerophospholipid synthesis: improved general method and new analogs containing photoactivable groups. Proc Natl Acad Sci U S A. 74:4315-9.
29. Watt MJ, Steinberg GR (2008) Regulation and function of triacylglycerol lipases in cellular metabolism. Biochem J. 414:313-25. 30. Nagan N, Hajra AK, Larkins LK, Lazarow P, Purdue PE, Rizzo WB, Zoeller RA. (1998) Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthesis: use of a novel two-step selection protocol. Biochem J. 332:273-9.
31. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino
K, Morihara T, Takeda M, Wood PL (2007) Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res. 48:2485-98.
32. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S and Kimura J ( 1991 ) Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 181:265-271. 33. Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS and Tanzi R (1997) ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 48:139-147.
34. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL and Pericak-Vance MA (1993) Gene dose of apolipoprotein E type
4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
35. Fahrenholz F (2007) Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4:412- 417.
36. Ghribi O, Larsen B, Schrag M and Herman MM (2006) High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 200:460-467.
37. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C and Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349:151- 154.
38. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, Hoyt RF, Jr., Neufeld ED, Remaley AT, Fredrickson DS, Brewer HB, Jr. and Santamarina-Fojo S (2002) The ATP binding cassette transporter Al (ABCAl) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA 99:407-412.
39. Lange Y, Ye J and Steck TL (2004) How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids. Proc Natl Acad Sci USA 101: 1 1664- 1 1667.
40. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I and Rydel RE (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10:243-254.
41. Meyer-Luehmann M, Spires- Jones TL, Prada C, Garcia- Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ and Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451:720-724.
42. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW and Mullan MJ (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 60:778-785.
43. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F and Fahrenholz F (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113:1456-1464.
44. Rong JX, Shapiro M, Trogan E and Fisher EA (2003) Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl AcadSci USA 100:13531-13536. 45. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak- Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ and et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
46. Scanlon SM, Williams DC and Schloss P (2001) Membrane cholesterol modulates serotonin transporter activity. Biochemistry 40:10507-10513.
47. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791.
48. Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426:900-904.
49. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B and Hayden MR (2002) Increased ABCAl activity protects against atherosclerosis. J Clin Invest 110:35-42.
50. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR and Van Berkel TJ (2006) Macrophage ATP -binding cassette transporter Al overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vase Biol 26:929-934. 51. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM and Holtzman DM (2008) Overexpression of ABCAl reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118:671-682. 52. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ and Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.

Claims

WHAT IS CLAIMED IS:
1. A compound according to the structure of formula I:
Figure imgf000054_0001
(I) wherein:
Ri and R2 are the same or different and selected from an alkyl or alkenyl hydrocarbon chain selected from the group consisting of: CH3(CH2)3-, CH3(CH2)S-, CH3(CH2)7-, CH3(CH2V, CH3(CH2),,-, CH3(CH2)U-, CH3(CH2),5-, CH3(CH2),,-, CH3(CH2),9-, CH3(CH2)2r, CH3(CH2)23-, CH3(CH2)3CH=CH(CH2)7-, CH3(CH2)5CH=CH(CH2)7-, CH3(CH2)7CH=CH(CH2)7-, CH3(CH2)4CH=CHCH2CH=CH(CH2)7-,
CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)7-, CH3CH2(CH=CH)-, CH3(CH2)3(CH=CH)- , CH3(CH2)5(CH=CH)-, CH3(CH2)7(CH=CH)-, CH3(CH2)9(CH=CH)-, CH3(CH2),, (CH=CH)- , CH3(CH2)13(CH=CH)-, CH3(CH2)15(CH=CH)-, CH3(CH2) 17(CH=CH)-, CH3(CH2), 9(CH=CH)-, CH3(CH2)2,(CH=CH)-, CH3(CH2)3CH=CH(CH2)5(CH=CH)-, CH3(CH2)5CH=CH(CH2)5(CH=CH)-, CH3(CH2)7CH=CH(CH2)5(CH=CH)-, CH3(CH2)4CH=CHCH2CH=CH(CH2)5(CH=CH),
CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)5(CH=CH)-, CH3(CH2)3CH=CH(CH2)7-, CH3(CH2)5CH=CH(CH2)7-, CH3(CH2)7CH=CH(CH2)7-, CH3(CH2)4(CH=CHCH2)2(CH2)6-, CH3CH2(CH=CHCH2)3(CH2)6-, CH3(CH2)4(CH=CHCH2)4(CH2)2-, CH3CH2(CH=CHCH2)5(CH2)2-, CH3(CH2)7CH=CH(CH2)i ,, and CH3CH2(CH=CHCH2)6CH2-
R3 is selected from the group consisting of fatty acids, carnitine, acetyl-D/L- carnitine, thiocarnitine, acetyl-D/L-thiocarnitine, creatine, norcarnitine, phosphocholine, lipoic acid, dihydrolipoic acid, phosphoethanolamine, phosphoserine, N-acetylcysteine, substituted or unsubstituted amino acid groups and groups of the structures shown below:
Figure imgf000055_0001
R4 and R5 are independently hydrogen or lower alkyl; R6 is hydrogen or lower alkyl; and R7 and Rg are independently hydrogen or lower alkyl, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
2. The compound of claim 1 , wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
3. The compound of claim 1, wherein said compound is selected from the group consisting of 2-acetoxy-4-(2-((4Z,7Z,l OZ, 13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19- hexaenoyloxy)-3-(hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium (PPI- 1019), (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(5-((/?)-l,2-dithiolan-3-yl)pentanoyloxy)-3- (hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1011) and (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(2-acetamido-3-mercaptopropanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1014).
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
Figure imgf000056_0001
(I) wherein Ri to Rg are as defined in claim 1, and including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
5. The pharmaceutical composition of claim 4, wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
6. The pharmaceutical composition of claim 4, wherein the compound is selected from the group consisting of 2-acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19- hexaenoyloxy)-3-(hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium (PPI- 1019), (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(5-((Λ)-l,2-dithiolan-3-yl)pentanoyloxy)-3- (hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1011) and (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(2-acetamido-3-mercaptopropanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1014).
7. A method of treating or preventing diseases of aging associated with increased membrane cholesterol, increased amyloid or decreased plasmalogen levels, comprising administering to a patient in need thereof, an effective amount of a compound of formula I:
Figure imgf000056_0002
(I) wherein Ri to R8 are as defined in claim 1, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, or a pharmaceutical composition comprising said compound admixed with a pharmaceutically acceptable carrier.
8. The method of claim 7, wherein R2 is CH3CH2(CH=CHCH2)6CHr.
9. The method of claim 7 wherein the compound is selected from the group consisting of 2-acetoxy-4-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19-hexaenoyloxy)-3- (hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan-l-aminium (PPI-1019), (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)- 1 -(5-((R)- 1 ,2-dithiolan-3-yl)pentanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1011) and (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(2- acetamido-3-mercaptopropanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI- 1014).
10. The method of claim 7 wherein the diseases of aging are selected from the group consisting of: neurodegeneration, cognitive impairment, dementia, cancer, and vascular disease.
11. The method of claim 10 wherein the neurodegeneration disease is selected from the group consisting of: Alzheimer's disease, Parkinson's disease and age-related macular degeneration.
12. The method of claim 10 wherein the cancer is selected from the group consisting of: prostate, lung, breast, ovarian, and kidney cancer.
13. The method of claim 10 wherein the vascular disease is selected from the group consisting of: atherosclerosis and hypercholesterolemia.
14. A method of treating or preventing diseases of the aging mediated by plasmalogen deficiency, by increasing PlsEtn levels to above control levels in either PlsEtn deficient or
PlsEtn sufficient systems by administering to a patient in need thereof an effective amount of a compound of formula I:
Figure imgf000058_0001
(I) wherein Ri to R8 are as defined in claim I, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, or a pharmaceutical composition comprising said compound admixed with a pharmaceutically acceptable carrier.
15. The method of claim 14, wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
16. A method of treating or preventing a disorder resulting from abnormal genetic expression of cholesterol transport proteins comprising administering to a patient in need thereof an effective amount of a compound of formula I:
Figure imgf000058_0002
(I) wherein Ri to R8 are as defined in claim I, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, or a pharmaceutical composition comprising said compound admixed with a pharmaceutically acceptable carrier.
17. The method of claim 16, wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
18. The method of claim 16, wherein the cholesterol transport protein is apolipoprotein E.
19. Use of a compound of formula I:
Figure imgf000059_0001
(I) wherein Ri to R8 are as defined in claim 1 , including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, or a pharmaceutical composition comprising said compound admixed with a pharmaceutically acceptable carrier, for treating or preventing diseases of aging associated with increased membrane cholesterol, increased amyloid or decreased plasmalogen levels.
20. The use of claim 19, wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
21. The use of claim 19 wherein the diseases of aging are selected from the group consisting of: neurodegeneration, cognitive impairment, dementia, cancer, and vascular disease.
22. The use of claim 21 wherein the neurodegeneration disease is selected from the group consisting of: Alzheimer's disease, Parkinson's disease and age-related macular degeneration.
23. The use of claim 21 wherein the cancer is selected from the group consisting of: prostate, lung, breast, ovarian, and kidney cancer.
24. The use of claim 21 wherein the vascular disease is selected from the group consisting of: atherosclerosis and hypercholesterolemia.
25. Use of a compound of formula I:
Figure imgf000059_0002
(I) wherein Ri to R8 are as defined in claim 1, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, or a pharmaceutical composition comprising said compound admixed with a pharmaceutically acceptable carrier, for treating or preventing diseases of the aging mediated by plasmalogen deficiency, by increasing PlsEtn levels to above control levels in either PlsEtn deficient or PlsEtn sufficient systems.
26. The use of claim 25, wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
27. Use of a compound of formula I:
Figure imgf000060_0001
(I) wherein Ri to R8 are as defined in claim 1 , including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, or a pharmaceutical composition comprising said compound admixed with a pharmaceutically acceptable carrier, for treating or preventing a disorder resulting from abnormal genetic expression of cholesterol transport proteins.
28. The use of claim 27, wherein R2 is CH3CH2(CH=CHCH2)6CH2-.
29. The use of claim 27, wherein the cholesterol transport protein is apolipoprotein E.
30. The use of any one of claims 19 to 29, wherein the compound is selected from the group consisting of 2-acetoxy-4-(2-((4Z,7Z, 1 OZ, 13Z,16Z,19Z)-docosa-4, 7,10, 13, 16, 19- hexaenoyloxy)-3-(hexadecyloxy)propoxy)-N,N,N-trimethyl-4-oxobutan- 1 -aminium (PPI- 1019), (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(5-((/?)-l,2-dithiolan-3-yl)pentanoyloxy)-3- (hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1011) and (4Z, 7Z, 1OZ, 13Z, 16Z, 19Z)-l-(2-acetamido-3-mercaptopropanoyloxy)-3-(hexadecyloxy)propan-2-yl docosa-4, 7, 10, 13, 16, 19-hexaenoate (PPI-1014).
31. A process for preparing a compound according to the structure of formula II:
Figure imgf000061_0001
(H) wherein Ri and R4 to Rg are as defined in claim 1 and R9 is a blocking group, and including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof, said process comprising reacting a compound of formula III:
Figure imgf000061_0002
(III) in a suitable solvent with a nucleophilic catalyst, a base and a blocking agent under conditions to form said compound of formula II, and
optionally purifying said compound of formula II.
32. The process of claim 31, wherein said blocking agent is a silane blocking agent.
33. The process of claim 32, wherein the silane blocking agent is a tert- butyldimethylsilyl halide and R9 is a tert-butyldimethylsilyl group.
34. The process of claim 31, wherein said nucleophilic catalyst is DMAP.
35. The process of claim 31 , wherein said base is triethylamine.
36. The process of claim 31, wherein said solvent comprises dimethylformamide (DMF) and CH2Cl2.
37. The process of claim 31 , wherein a solution of said compound of formula III, said nucleophilic catalyst, and said base in said solvent is cooled to 0 to 5 °C prior to addition of said blocking agent.
38. The process of claim 37, wherein said reaction is carried out at a temperature of 15 to 25 °C.
39. The process of claim 38, wherein said reaction is carried out at about 20 0C.
40. The process of claim 39, wherein said reaction is allowed to proceed for up to 20 hours.
41. A compound according to the structure of formula II:
Figure imgf000062_0001
(H) wherein Ri and R4 to R8 are as defined in claim 1 and R9 is a blocking group, including racemates or isolated stereoisomers and pharmaceutically acceptable salts or esters thereof.
42. The compound of claim 41 , wherein said blocking group is a silyl blocking group.
43. The compound of claim 41, wherein R9 is a tert-butyldimethylsilyl group.
PCT/CA2009/001853 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging Ceased WO2010071988A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN200980157183.5A CN102369193B (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions comprising plasmalogen compounds and methods for treating diseases of aging
KR1020117015617A KR101810988B1 (en) 2008-12-22 2009-12-18 Plasmalogen Compounds, Pharmaceutical Compositions Containing The Same and Methods for Treating Diseases of the Aging
RU2011124579/04A RU2546108C2 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing them and methods of treating age-related diseases
CA2746831A CA2746831C (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
SG2011045994A SG172340A1 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
AU2009329784A AU2009329784B2 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
EP09833973.2A EP2382201B1 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
BRPI0922619A BRPI0922619A8 (en) 2008-12-22 2009-12-18 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR TREATING DISEASES OF AGING
MX2011006795A MX350291B (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging.
JP2011541046A JP5740312B2 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same, and methods for treating diseases due to aging
US13/141,035 US9334235B2 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
IL213409A IL213409A0 (en) 2008-12-22 2011-06-06 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13969508P 2008-12-22 2008-12-22
US61/139,695 2008-12-22

Publications (2)

Publication Number Publication Date
WO2010071988A1 true WO2010071988A1 (en) 2010-07-01
WO2010071988A8 WO2010071988A8 (en) 2011-07-21

Family

ID=42286823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/001853 Ceased WO2010071988A1 (en) 2008-12-22 2009-12-18 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging

Country Status (17)

Country Link
US (1) US9334235B2 (en)
EP (1) EP2382201B1 (en)
JP (2) JP5740312B2 (en)
KR (1) KR101810988B1 (en)
CN (2) CN105859680A (en)
AR (2) AR074854A1 (en)
AU (1) AU2009329784B2 (en)
BR (1) BRPI0922619A8 (en)
CA (1) CA2746831C (en)
IL (1) IL213409A0 (en)
MX (1) MX350291B (en)
MY (1) MY169797A (en)
RU (1) RU2546108C2 (en)
SG (1) SG172340A1 (en)
TW (1) TWI475989B (en)
UY (1) UY32359A (en)
WO (1) WO2010071988A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013053110A (en) * 2011-09-05 2013-03-21 Teikyo Univ Oral administration preparation
JP2013053109A (en) * 2011-09-05 2013-03-21 Teikyo Univ Agent for increasing phospholipid-bound dha
WO2016041013A1 (en) * 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
US10024857B2 (en) 2009-10-01 2018-07-17 Med-Life Discoveries Lp Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
WO2019208392A1 (en) 2018-04-27 2019-10-31 株式会社レオロジー機能食品研究所 Novel plasmalogen derivative
WO2023027021A1 (en) * 2021-08-23 2023-03-02 株式会社レオロジー機能食品研究所 Novel plasmalogen derivative
WO2023089986A1 (en) 2021-11-22 2023-05-25 株式会社 レオロジー機能食品研究所 Compound, racemate of said compound, salt of said compound or said racemate, composition, anti-inflammatory agent, therapeutic agent for dementia, and therapeutic agent for rett syndrome
WO2024111529A1 (en) * 2022-11-21 2024-05-30 株式会社 レオロジー機能食品研究所 Agent for increasing brain plasmalogen, and use of oral composition and compound for increasing brain plasmalogen

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100060A2 (en) * 2009-03-04 2010-09-10 Nestec S.A. Method for increasing endogenous plasmalogen levels in mammals
WO2015064960A1 (en) 2013-10-29 2015-05-07 울산대학교 산학협력단 Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component
CN108276438B (en) * 2018-02-02 2020-05-22 中国海洋大学 A kind of preparation method of EPA plasmalogen and application thereof
WO2020009173A1 (en) * 2018-07-06 2020-01-09 丸大食品株式会社 Plasmalogen-containing composition
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN112321446A (en) * 2020-11-25 2021-02-05 华南理工大学 Synthesis method of amide derivative
CN113150270A (en) * 2021-03-19 2021-07-23 广东丁沃生医疗器械有限公司 Phospholipid polymer and preparation method and application thereof
JP7704407B2 (en) * 2021-08-04 2025-07-08 株式会社 レオロジー機能食品研究所 Cancer treatment composition
WO2025057845A1 (en) * 2023-09-11 2025-03-20 株式会社 レオロジー機能食品研究所 Anti-aging agent, oral composition for anti-aging, and use of compound
CN119876292B (en) * 2025-03-27 2025-06-03 浙江省白马湖实验室有限公司 Preparation method and application of amide plasmalogen compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095275A1 (en) 2007-02-08 2008-08-14 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
FR2736265B1 (en) 1995-07-07 1997-09-26 Forgeot Marcel NOVEL COMPOSITIONS BASED ON PHOSPHOGLYCERO ETHERS AND THEIR USE IN THE TREATMENT OF NEURO-DEGENERATIVE DISEASES
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP2004026803A (en) 2002-03-29 2004-01-29 Nof Corp Nerve cell death preventive
US20080020472A1 (en) 2005-11-22 2008-01-24 Frantz Biomarkers, Llc Method for detecting an inflammatory disease or cancer
CA2689848A1 (en) 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
US20080021000A1 (en) 2006-07-19 2008-01-24 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
JP2008125365A (en) * 2006-11-16 2008-06-05 Kagoshima Univ High purity plasmalogen preparation method
US20100105635A1 (en) 2007-01-30 2010-04-29 Tohoku University Composition for prevention or treatment of disease associated with amyloidosis through inhibition of amyloid protein aggregation and promotion of amyloid protein degradation
CA2680748C (en) 2007-04-13 2012-08-28 Phenomenome Discoveries Inc. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095275A1 (en) 2007-02-08 2008-08-14 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, pages: 18042
"The Condensed Chemical Dictionary", 1981
ARAKI WKITAGUCHI NTOKUSHIMA YISHII KARATAKE HSHIMOHAMA SNAKAMURA SKIMURA J: "Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture", BIOCHEM BIOPHYS RES COMMUN, vol. 181, 1991, pages 265 - 271, XP001148994, DOI: 10.1016/S0006-291X(05)81412-3
BEEL AJMOBLEY CKKIM HJTIAN FHADZISELIMOVIC AJAP BPRESTEGARD JHSANDERS CR: "Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?", BIOCHEMISTRY, vol. 47, 2008, pages 9428 - 46
BLACKER D, HAINES JL, RODES L, TERWEDOW H, GO RC, HARRELL LE, PERRY RT, BASSETT SS, CHASE G, MEYERS D, ALBERT MS, TANZI R: " ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative", NEUROLOGY, vol. 48, pages 139 - 147, XP055250816, DOI: 10.1212/WNL.48.1.139
CALDERINI GBONETTI ACBATTISTELLA ACREWS FTTOFFANO G: "Biochemical changes of rat brain membranes with aging", NEUROCHEM RES, vol. 8, 1983, pages 483 - 92
CAMPBELL AMCHAN SH: "Mitochondrial membrane cholesterol, the voltage dependent anion channel (VDAC), and the Warburg effect", J BIOENERG BIOMEMBR, 2008
CORDER EHSAUNDERS AMSTRITTMATTER WJSCHMECHEL DEGASKELL PCSMALL GWROSES ADHAINES JLPERICAK-VANCE MA: "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families", SCIENCE, vol. 261, 1993, pages 921 - 923, XP000619874, DOI: 10.1126/science.8346443
CORRIGAN FMHORROBIN DFSKINNER ERBESSON JACOOPER MB: "Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content", INT J BIOCHEM CELL BIOL, vol. 30, 1998, pages 197 - 207, XP001064439, DOI: 10.1016/S1357-2725(97)00125-8
CULTLER RGKELLY JSTORIE KPEDERSEN WATAMMARA AHATANPAA KTRONCOSO JCMATTSON MP: "Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease", PROC NATL ACAD SCI U S A., vol. 101, 2004, pages 2070 - 5, XP008041296, DOI: 10.1073/pnas.0305799101
DIESTEL AAKTAS OHACKEL DHAKE IMEIER SRAINE CSNITSCH RZIPP FULLRICH O: "Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage", J EXP MED, vol. 198, 2003, pages 1729 - 40
DISTL RMESKE VOHM TG: "Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons", ACTA NEUROPATHOL, vol. 101, 2001, pages 547 - 54
FAHRENHOLZ F: "Alpha-secretase as a therapeutic target", CURR ALZHEIMER RES, vol. 4, 2007, pages 412 - 417
GHRIBI OLARSEN BSCHRAG MHERMAN MM: "High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus", EXP NEUROL, vol. 200, 2006, pages 460 - 467
GOODENOWE DBCOOK LLLIU JLU YJAYASINGHE DAAHIAHONU PWHEATH DYAMAZAKI YFLAX JKRENITSKY KF: "Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia", J LIPID RES, vol. 48, 2007, pages 2485 - 98, XP008122068, DOI: 10.1194/JLR.P700023-JLR200
GRIMM MOGRIMM HSTOMIC IBEYREUTHER KHARTMANN TBERGMANN C: "Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels", J BIOL CHEM, vol. 283, 2008, pages 11302 - 11
GUO JCHI SXU HJIN GQI Z: "Effects of cholesterol levels on the excitability of rat hippocampal neurons", MOL MEMBR BIOL, vol. 25, 2008, pages 216 - 23
GUPTA CMRADHAKRISHNAN RKHORANA HG: "Glycerophospholipid synthesis: improved general method and new analogs containing photoactivable groups", PROC NATL ACAD SCI U S A., vol. 74, 1977, pages 4315 - 9
H. ANSEL: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995, pages: 108 - 109
HAGER MHSOLOMON KRFREEMAN MR: "The role of cholesterol in prostate cancer", CURR OPIN CLIN NUTR METAB CARE, vol. 9, 2006, pages 379 - 85
HASHIMOTO MHOSSAIN SMASUMURA S: "Effect of aging on plasma membrane fluidity of rat aortic endothelial cells", EXP GERONTOL, vol. 34, 1999, pages 687 - 98
HASHIMOTO MHOSSAIN STANABE YSHIDO O: "Effects of aging on the relation of adenyl purine release with plasma membrane fluidity of arterial endothelial cells. Prostoglandins Leukot", ESSENT. FATTY ACIDS., vol. 73, 2005, pages 475 - 83
HOFMAN AOTT ABRETELER MMBOTS MLSLOOTER AJVAN HARSKAMP FVAN DUIJN CNVAN BROECKHOVEN CGROBBEE DE: "Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study", LANCET, vol. 349, 1997, pages 151 - 154, XP005061658, DOI: 10.1016/S0140-6736(96)09328-2
JOYCE CWAMAR MJLAMBERT GVAISMAN BLPAIGEN BNAJIB-FRUCHART JHOYT RF, JR.NEUFELD EDREMALEY ATFREDRICKSON DS: "The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice", PROC NATL ACAD SCI U S A, vol. 99, 2002, pages 407 - 412
KESSLER ARKESSLER BYEHUDA S: "Changes in the cholesterol level, cholesterol-to-phospholipid mole ratio, and membrane lipid microviscosity in rat brain induced by age and a plant oil mixture", BIOCHEM PHARMACOL, vol. 34, 1985, pages 1120 - 1, XP023849135, DOI: 10.1016/0006-2952(85)90620-3
KROGSGAARD-LARSEN: "Textbook of Drug Design and Development", 1996, pages: 152 - 191
LANGE YYE JSTECK TL: "How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids", PROC NATL ACAD SCI U S A, vol. 101, 2004, pages 11664 - 11667
LEWIN MBTIMIRAS PS: "Lipid changes with aging in cardiac mitochondrial membranes", MECH AGEING DEV, vol. 24, 1984, pages 343 - 51, XP025442246, DOI: 10.1016/0047-6374(84)90119-2
LI CMCLARK MERUDOLF MCURCIO CA: "Distribution and composition of esterified and unesterified cholesterol in extra-macular drusen", EXP EYE RES, vol. 85, 2007, pages 192 - 201, XP022169757, DOI: 10.1016/j.exer.2007.04.002
MATTSON MP, CHENG B, CULWELL AR, ESCH FS, LIEBERBURG I, RYDEL RE: "Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein", NEURON, vol. 10, 1993, pages 243 - 254
MEYER-LUEHMANN M, SPIRES-JONES TL, PRADA C, GARCIA-ALLOZA M, DE CALIGNON A, ROZKALNE A, KOENIGSKNECHT-TALBOO J, HOLTZMAN DM, BACSK: "Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease", NATURE, vol. 451, 2008, pages 720 - 724
MIERSCH SESPEY MGCHAUBE RAKARCA ATWETEN RANANVORANICH SMUTUS B: "Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling", J BIOL CHEM, vol. 283, 2008, pages 18513 - 21
MODI HRKATYARE SSPATEL MA: "Ageing-induced alterations in lipid/phospholipid profiles of rat brain and liver mitochondria: implications for mitochondrial energy-linked functions", J MEMBR BIOL, vol. 221, 2008, pages 51 - 60, XP019585671
MORI TPARIS DTOWN TROJIANI AMSPARKS DLDELLEDONNE ACRAWFORD FABDULLAH LIHUMPHREY JADICKSON DW: "Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice", J NEUROPATHOL, vol. 60, 2001, pages 778 - 785
NAGAN NHAJRA AKLARKINS LKLAZAROW PPURDUE PERIZZO WBZOELLER RA: "Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthesis: use of a novel two-step selection protocol", BIOCHEM J, vol. 332, 1998, pages 273 - 9
POSTINA R, SCHROEDER A, DEWACHTER I, BOHL J, SCHMITT U, KOJRO E, PRINZEN C, ENDRES K, HIEMKE C, BLESSING M, FLAMEZ P, DEQUENNE A, : "A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model", J CLIN INVEST, vol. 113, 2004, pages 1456 - 1464
RONG JXSHAPIRO MTROGAN EFISHER EA: "Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading", PROC NATL, vol. 100, 2003, pages 13531 - 13536
SANTIAGO JGUZMAN GRROJAS LVMARTI RASMAR-ROVIRA GASANTANA LFMCNAMEE MLASALDE-DOMINICCI JA: "Probing the effects of membrane cholesterol in the Torpedo californica acetylcholine receptor and the novel lipid-exposed mutation alpha C418W in Xenopus oocytes", J BIOL CHEM, vol. 276, 2001, pages 46523 - 32
SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D, GEORGE-HYSLOP PH, PERICAK-VANCE MA, JOO SH, ROSI BL, GUSELLA JF, CRAPPER-MACLACHLAN DR,: "Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease", NEUROLOGY, vol. 43, 1993, pages 1467 - 1472, XP000198203
SCANLON SMWILLIAMS DCSCHLOSS P: "Membrane cholesterol modulates serotonin transporter activity", BIOCHEMISTRY, vol. 40, 2001, pages 10507 - 10513
See also references of EP2382201A4
SELKOE DJ: "Alzheimer's disease is a synaptic failure", SCIENCE, vol. 298, 2002, pages 789 - 791, XP008075043, DOI: 10.1126/science.1074069
SELKOE DJ: "Folding proteins in fatal ways", NATURE, vol. 426, 2003, pages 900 - 904, XP002534016, DOI: 10.1038/nature02264
SHIN JTHOMPSON DH: "Direct synthesis of plasmenylcholine from allyl-substituted glycerols", J ORG CHEM, vol. 68, 2003, pages 6760 - 6
SIGLE JPZANDER JEHRET AHONEGGER JJACKISCH RFEUERSTEIN TJ: "High potassium-induced activation of choline-acetyltransferase in human neocortex: implications and species differences", BRAIN RES BULL, vol. 60, 2003, pages 255 - 62
SIMONS MKELLER PDE STROOPER BBEYREUTHER KDOTTI CGSIMONS K: "Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons", PROC NATL ACAD SCI USA, vol. 95, 1998, pages 6460 - 4, XP002992103, DOI: 10.1073/pnas.95.11.6460
SINGARAJA RRFIEVET CCASTRO GJAMES ERHENNUYER NCLEE SMBISSADA NCHOY JCFRUCHART JCMCMANUS BM: "Increased ABCA1 activity protects against atherosclerosis", J CLIN INVEST, vol. 110, 2002, pages 35 - 42
STAMATOV, SD ET AL.: "Regioselective and stereospecific acylation across oxirane- and silyloxy systems as a novel strategy to the synthesis of enantiomerically pure mono-, di- and triglycerides", ORGANIC AND BIOMOLECULAR CHEMISTRY, vol. 5, 2007, pages 3787 - 3800, XP008152333 *
STREIT WJSPARKS DL: "Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits", J MOL MED, vol. 75, 1997, pages 130 - 8
THIRUMANGALAKUDI LPRAKASAM AZHANG RBIMONTE-NELSON HSAMBAMURTI KKINDY MSBHAT NR: "High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice", J NEUROCHEM, vol. 106, 2008, pages 475 - 85
THOMPSON, DH ET AL.: "Synthesis ofChiral Diether and Tetraether Phospholipids: Regiospecific Ring Opening of Epoxy Alcohol intermediates derived from Asymmetric Epoxidation", JOURNAL OF ORGANIC CHEMISTRY, vol. 59, 1994, pages 2945 - 2955, XP002231653 *
VAN ECK M, SINGARAJA RR, YE D, HILDEBRAND RB, JAMES ER, HAYDEN MR, VAN BERKEL TJ: "Macrophage ATP-binding cassette transporter Al overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice", ARTERIOSCLER THROMB VASC BIOL, vol. 26, 2006, pages 929 - 934
VEJUX AMALVITTE LLIZARD G: "Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis", BRAZ J MED BIOL RES, vol. 41, 2008, pages 545 - 56
WAHRLE SE, JIANG H, PARSADANIAN M, KIM J, LI A, KNOTEN A, JAIN S, HIRSCH-REINSHAGEN V, WELLINGTON CL, BALES KR, PAUL SM AND HOLTZM: "Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease", CLIN INVEST, vol. 118, 2008, pages 671 - 682
WALSH DMKLYUBIN IFADEEVA JVCULLEN WKANWYL RWOLFE MSROWAN MJSELKOE DJ: "Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo", NATURE, vol. 416, 2002, pages 535 - 539, XP002348771, DOI: 10.1038/416535a
WATT MJSTEINBERG GR: "Regulation and function of triacylglycerol lipases in cellular metabolism", BIOCHEM J, vol. 414, 2008, pages 313 - 25
WOLOZIN BWANG SWLI NCLEE ALEE TAKAZIS LE: "Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease", BMC MED, vol. 5, 2007, pages 20, XP021030239, DOI: 10.1186/1741-7015-5-20
WU CCSU MJCHI JFWU MHLEE YT: "Comparison of aging and hypercholesterolemic effects on the sodium inward currents in cardiac myocytes", LIFE SCI, vol. 61, 1997, pages 1539 - 51
XIA, J ET AL.: "The chemical synthesis of ether phospholipids from D-mannitol and their properties", TETRAHEDRON: ASYMMETRY, vol. 8, no. 18, 1997, pages 3131 - 3142, XP008156201 *
XIU JNORDBERG AQI XGUAN ZZ: "Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes", NEUROCHEM INT, vol. 49, 2006, pages 459 - 65

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10024857B2 (en) 2009-10-01 2018-07-17 Med-Life Discoveries Lp Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US10656155B2 (en) 2009-10-01 2020-05-19 Med-Life Discoveries Lp Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US11079385B2 (en) 2009-10-01 2021-08-03 Med-Life Discoveries Lp Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
JP2013053109A (en) * 2011-09-05 2013-03-21 Teikyo Univ Agent for increasing phospholipid-bound dha
JP2013053110A (en) * 2011-09-05 2013-03-21 Teikyo Univ Oral administration preparation
WO2016041013A1 (en) * 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
US12060379B2 (en) 2018-04-27 2024-08-13 Institute of Rheological Functions of Food Plasmalogen derivatives
WO2019208392A1 (en) 2018-04-27 2019-10-31 株式会社レオロジー機能食品研究所 Novel plasmalogen derivative
KR20210005190A (en) 2018-04-27 2021-01-13 가부시키가이샤 레오로지 키노쇼쿠힝겐큐죠 Novel Plasmalogen Derivatives
WO2023027021A1 (en) * 2021-08-23 2023-03-02 株式会社レオロジー機能食品研究所 Novel plasmalogen derivative
JPWO2023027021A1 (en) * 2021-08-23 2023-03-02
JP7629164B2 (en) 2021-08-23 2025-02-13 株式会社 レオロジー機能食品研究所 New plasmalogen derivatives
WO2023089986A1 (en) 2021-11-22 2023-05-25 株式会社 レオロジー機能食品研究所 Compound, racemate of said compound, salt of said compound or said racemate, composition, anti-inflammatory agent, therapeutic agent for dementia, and therapeutic agent for rett syndrome
KR20240113765A (en) 2021-11-22 2024-07-23 가부시키가이샤 레오로지 키노쇼쿠힝겐큐죠 Compounds, racemates thereof, salts thereof, compositions, anti-inflammatory agents, therapeutic agents for dementia and therapeutic agents for Rett syndrome
EP4438610A4 (en) * 2021-11-22 2025-11-19 Inst Of Rheological Function Of Food Co Ltd Compound, racemate of this compound, salt of this compound or this racemate, composition, anti-inflammatory, therapeutic agent for dementia and therapeutic agent for Rett syndrome
WO2024111529A1 (en) * 2022-11-21 2024-05-30 株式会社 レオロジー機能食品研究所 Agent for increasing brain plasmalogen, and use of oral composition and compound for increasing brain plasmalogen

Also Published As

Publication number Publication date
KR101810988B1 (en) 2017-12-20
CN105859680A (en) 2016-08-17
JP2012512816A (en) 2012-06-07
AU2009329784A1 (en) 2011-07-07
TWI475989B (en) 2015-03-11
RU2546108C2 (en) 2015-04-10
EP2382201A4 (en) 2015-11-18
US9334235B2 (en) 2016-05-10
CA2746831A1 (en) 2010-07-01
CN102369193B (en) 2016-05-04
MX2011006795A (en) 2011-09-26
US20130116312A2 (en) 2013-05-09
US20120035250A1 (en) 2012-02-09
CN102369193A (en) 2012-03-07
AR074854A1 (en) 2011-02-16
MY169797A (en) 2019-05-15
RU2011124579A (en) 2013-01-27
TW201034662A (en) 2010-10-01
AU2009329784B2 (en) 2016-08-25
CA2746831C (en) 2013-11-26
SG172340A1 (en) 2011-07-28
EP2382201B1 (en) 2022-08-24
EP2382201A1 (en) 2011-11-02
WO2010071988A8 (en) 2011-07-21
JP2015145388A (en) 2015-08-13
JP5740312B2 (en) 2015-06-24
AR117572A2 (en) 2021-08-18
BRPI0922619A8 (en) 2023-01-10
UY32359A (en) 2010-05-31
KR20110104002A (en) 2011-09-21
MX350291B (en) 2017-09-04
IL213409A0 (en) 2011-07-31
BRPI0922619A2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
EP2382201B1 (en) Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
EP2348866B1 (en) Oxidized lipid compounds and uses thereof
US20220273682A1 (en) Acefapc for the treatment of acetylcholine-dependent diseases
US8999960B2 (en) Oxidized thiophospholipid compounds and uses thereof
EP3066106B1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
CA2817362A1 (en) Lipoyl compounds and their use for treating ischemic injury
KR20090112631A (en) Omega-3 Lipid Compound
WO2016130417A1 (en) Omega-3 fatty acid prodrug compounds and uses thereof
HK1157762B (en) Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
HK1157762A (en) Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
US8629175B2 (en) Functional food additives
HK1155906B (en) Oxidized lipid compounds and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980157183.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09833973

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 593285

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2011541046

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009329784

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2746831

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/006795

Country of ref document: MX

Ref document number: 12011501298

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20117015617

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009329784

Country of ref document: AU

Date of ref document: 20091218

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009833973

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3038/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011124579

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13141035

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0922619

Country of ref document: BR

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, TENDO EM VISTA QUE A APRESENTADA ESTA DATADA DE 14/07/2011, SENDO QUE A PETICAO DE ENTRADA NA FASE NACIONAL OCORREU EM 22/06/2011, E O TEXTO DA MESMA NAO POSSUI CLAUSULA QUE RATIFICA OS ATOS PRATICADOS ANTERIORMENTE.

REG Reference to national code

Ref country code: BR

Ref legal event code: ERR

Ref document number: PI0922619

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULACAO DA PUBLICACAO CODIGO 1.5 NA RPI NO 2368 DE 24/05/2016, POR TER SIDO INDEVIDA.

ENP Entry into the national phase

Ref document number: PI0922619

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110622